

ASTHMANET

APRIL - Azithromycin for Preventing the development of upper Respiratory tract Illness into Lower respiratory tract symptoms in children

Note: This protocol was originally comprised of two separate but linked trials that targeted preschool aged children with recurrent severe episodes of lower respiratory tract symptoms. The second component of the protocol was named OCELOT (Oral Corticosteroids for treating Episodes of significant Lower respiratory Tract symptoms in children). On April 19, 2013, the AsthmaNet Data and Safety Monitoring Board recommended discontinuation of OCELOT due to futility as described in Appendix 5.

Terminology used in the APRIL Protocol document does not lend itself to concise language required for manuscript publication. The following table provides a link between the concise terminology used the manuscript and the expanded terminology used in the protocol.

Manuscript Terminology	Protocol Terminology
Treated Respiratory Tract Illness (RTI)	Respiratory Tract Illness (RTI) for which the participant had opportunity to take more than one dose of study medication before meeting Study Failure criteria. Illnesses that progressed to Study Failure on the same day were not counted as Treated RTI. Note: Inclusion in the primary analysis was not dependent on actually taking any study medication, only on having the opportunity to take more than one dose.
Severe Lower Respiratory Tract Illness (SLRTI)	Clinically significant lower respiratory tract symptoms (also called APRIL Treatment Failure) occurring within 14 days of the start of a treated RTI.
Early termination	Study Failure occurring more than 14 days after the start of a treated RTI or on the same day that study medication was initiated.
End of follow-up	The end of the study follow-up period (either 52 or 78 weeks depending on whether it occurred prior to the protocol revision) or the occurrence of a 4 th Treated RTI that did not progress to SLRTI.
Drop out	Lost to follow-up or withdrew consent (voluntarily or by study physician discretion) prior to the occurrence of Study Failure, 4 th Treated RTI or reaching the end of the follow-up period.

- I. TRIAL SUMMARY..... 5
- II. BACKGROUND AND RATIONALE 5
 - A. INTRODUCTION – OVERVIEW OF THE CLINICAL PROBLEMS 5
 - B. REVIEW OF CLINICAL TRIALS RELEVANT TO THIS PROTOCOL 8
 - C. SELECTION OF INTERVENTIONS FOR THIS TRIAL 12
 - D. RATIONALE FOR SELECTED STUDY POPULATION 13
 - E. SELECTION OF STUDY MEDICATIONS, DOSAGES, AND DURATION..... 15
 - F. PRIMARY OUTCOME MEASURES 17
 - G. RATIONALE FOR GENETIC PREDICTOR ANALYSES 18
 - H. RATIONALE FOR RESPIRATORY VIRUS ANALYSES..... 18
 - I. RESEARCH QUESTIONS 19
- III. HYPOTHESES TO BE TESTED BY THESE TRIALS 19
 - A. PRIMARY HYPOTHESES 19
 - B. SECONDARY AND EXPLORATORY HYPOTHESES 19
- IV. STUDY PROTOCOL OVERVIEW AND DESIGN 20
- V. PROTOCOL..... 21
 - A. STUDY GROUPS..... 21
 - B. INCLUSION CRITERIA 22
 - C. EXCLUSION CRITERIA..... 22
 - D. STUDY TREATMENTS..... 24
 - E. VISIT SPECIFIC PROCEDURES 24
 - F. OUTCOME VARIABLES 26
 - G. RANDOMIZATION 26
 - H. CRITERIA FOR STARTING APRIL THERAPY 27
 - I. CRITERIA FOR STUDY TREATMENT FAILURE AND STARTING OPEN-LABEL CORTICOSTEROID TREATMENT 29
 - J. CRITERIA FOR URGENT MEDICAL EVALUATION DURING OPEN-LABEL CORTICOSTEROIDS TREATMENT DURING STUDY FAILURE 31
 - K. SYMPTOMS REQUIRING UNSCHEDULED VISITS OR IMMEDIATE MEDICAL ATTENTION AT ANYTIME DURING THE STUDY 31
 - L. NON-STUDY DRUGS 33
 - M. RECRUITMENT 34
 - N. DRUG SUPPLIES 34
 - O. ADHERENCE..... 34
 - P. EDUCATION 34
 - Q. RETENTION..... 34
 - R. MONITORING FOR ADVERSE EFFECTS OF TREATMENT 35
 - S. SPECIAL STUDY TECHNIQUES 35
 - T. RISKS/BENEFITS..... 38
 - U. ANTICIPATED RESULTS 39
- VI. ADVERSE EVENTS..... 39
 - A. DEFINITION OF AN ADVERSE EVENT 39
 - B. APRIL: MONITORING OF ADVERSE EVENTS RELATED TO AZITHROMYCIN 39
 - C. ADVERSE EVENTS UNRELATED TO RESPIRATORY SYMPTOMS/ASTHMA..... 40
- VII. STATISTICAL DESIGN AND ANALYSIS 41
 - A. APRIL: OVERVIEW..... 41
 - B. APRIL: ANALYSIS 42
 - C. APRIL: SAMPLE SIZE JUSTIFICATION..... 43
 - D. APRIL: INTERIM ANALYSES AND DATA MONITORING..... 44
- VIII. SIGNIFICANCE 45
- IX. APPENDICES 46

X. REFERENCES.....58

I. TRIAL SUMMARY

This protocol is comprised of a clinical trial that targets preschool aged children with recurrent severe episodes of lower respiratory tract symptoms.

APRIL is a Prevention Study to examine the efficacy of a macrolide antibiotic (azithromycin 12mg/kg once daily for 5 days, maximum dose 500mg/day) versus placebo administered at the early signs of respiratory tract illnesses (RTI) and continued for 5 days in attenuating the progression of an upper RTI into development of clinically significant lower respiratory tract (LRT) symptoms. The endpoint (and primary outcome measure) for APRIL is the number of RTI that do not progress to Treatment Failure (as defined in Section II.F.) APRIL therapy may be used during up to 4 respiratory tract illnesses over the 78 week duration of the trial. If APRIL Treatment Failure is achieved, the participant will be started on open-label oral corticosteroids.

Note: The APRIL protocol was originally designed as a 52-week study allowing participants to experience up to 3 respiratory tract illnesses instead of 4. The protocol was extended to 78 weeks in June 2012 because the North American 2011/2012 viral season was unusually mild and it was apparent that the power of the APRIL study had been compromised due to the unexpectedly low rate of respiratory tract illnesses in the study population. At that time, approximately one-half of the study population had been enrolled. Of those, 60% were still in the original 52-week APRIL follow-up and 40% had completed the 52-week APRIL follow-up. All participants enrolled after the protocol change entered the 78-week follow-up period. Participants enrolled before the protocol change and still in the 52-week follow-up at the time of the protocol change were invited to join the 78-week follow-up and reconsented if they agreed. Participants who declined to join the 78-week follow-up were permitted to complete the 52-week follow-up under their original consent.

This trial is designed to identify a novel treatment approach (i.e., azithromycin) in this understudied and suboptimally managed population. Given the high levels of morbidity associated with these frequent episodes in young children, physicians and parents need guidance as to the appropriate strategies for episode progression. ***This trial will determine if the intervention tested can safely prevent such episodes, thereby reducing the morbidity of this common and difficult to treat problem.***

II. BACKGROUND AND RATIONALE

A. INTRODUCTION – OVERVIEW OF THE CLINICAL PROBLEMS

APRIL: PREVENTION OF EPISODES OF SIGNIFICANT LOWER RESPIRATORY TRACT SYMPTOMS

Among preschool aged children with recurrent clinically significant episodes of LRT symptoms, very little evidence is available to guide therapy. These children experience disproportionately high morbidity and health care utilization, including a 50% greater rate of ambulatory visits, nearly double the rate of ED visits, and nearly triple the rate of hospitalization relative to school age

children¹. Currently available asthma controller medications can decrease exacerbation rates. Indeed, the NHLBI Childhood Asthma Research and Education (CARE) Network Prevention of Early Asthma in Kids (PEAK) trial demonstrated that among preschool children at high risk for asthma, daily therapy with low dose ICS significantly reduced the likelihood of exacerbation requiring oral corticosteroids (OCS) by approximately 35% relative to placebo. Importantly, however, the rate of such exacerbations in the ICS group was still substantial at 57.4/100 child-years, clearly demonstrating the incomplete protection afforded by daily ICS therapy². Thus, identification of novel treatment approaches that attenuate the severity of these episodes would provide substantial benefit to this understudied and suboptimally managed population.

Although preschool wheezing leads to substantial morbidity, few definitive treatment studies have been performed in this age group leading to limited evidence based recommendations³. These clinical trials have examined several therapeutic strategies in preschool children who experience recurrent episodes of LRT symptoms but who remain minimally symptomatic or asymptomatic between episodes. Strategies examined have included both episodic and daily use of controller medications (ICS and LTRA) and are outlined below. However, the results have been overall disappointing either in terms of a lack of efficacy in reducing OCS use, an incomplete protection from exacerbations, or an effect on linear growth.

Inhaled corticosteroids: Maintenance daily low-dose ICS over a 2-year interval in the PEAK trial reduced the rate of exacerbations requiring OCS, increased the proportion of episode free days (EFDs), reduced supplemental controller medications and improved lung function, but was associated with slowed growth, compared to placebo, in high-risk preschool children with a positive asthma predictive index².

Given the episodic nature of wheezing among preschool children, which typically occurs during RTI, predominately triggered by viral infection, treatment strategies initiated at the onset of an RTI in at-risk preschool children would seem an especially appropriate strategy. The NHLBI CARE Network's Acute Intervention Management Strategies (AIMS) trial tested treatment strategies in recurrent wheezing toddlers in a randomized three-arm double-blind placebo-controlled (DBPC) parallel trial that compared high-dose ICS or montelukast to conventional therapy with albuterol. AIMS showed that intermittent high-dose ICS compared to conventional therapy initiated at the onset of a RTI modestly reduced the severity of the RTI and did not slow growth, but also did not reduce exacerbations requiring OCS⁴. Three earlier DBPC studies of small size (N = 24 - 55) reported that episodic high-dose ICS started with RTI led to improvement in symptoms, but also did not affect exacerbations⁵⁻⁷. A recent randomized double-blind placebo-controlled trial in toddlers with a severe exacerbation during the prior year reported a significant reduction (~50%) in rate of exacerbations requiring OCS with intermittent very high-dose ICS at the time of RTI, but with associated modest but significant detrimental growth effects in terms of height and weight⁸. The CARE Network's Maintenance vs. Intermittent Inhaled Steroids in Wheezing Toddlers (MIST) trial is currently comparing the effect of two regimens of ICS administration (maintenance low-dose ICS versus intermittent high-dose ICS at the onset of respiratory tract illnesses) on the rate of

exacerbations requiring systemic corticosteroids in preschool children with recurrent wheezing, positive asthma predictive index and a prior year severe wheezing exacerbation.

Leukotriene receptor antagonists: Maintenance daily therapy with montelukast in recurrent wheezing preschool children (toddlers) reduced overall exacerbations, but not those, presumably more severe that required systemic corticosteroids in a yearlong randomized DBPC trial⁹. Moreover, Robertson et al reported that intermittent treatment with montelukast once daily for at least 7 days compared to placebo in a randomized DBPC parallel multicenter center led to a reduction in health care utilization, symptoms, albuterol use, and wheezing illness associated child/parent absenteeism, but not in the rate of exacerbations requiring systemic corticosteroids (PRE-EMPT study)¹⁰. The AIMS trial also showed that episodic use of montelukast compared to conventional therapy initiated at the onset of a RTI reduced the severity of the RTI, but did not reduce exacerbations requiring OCS⁴.

Alternative treatment strategies: Since traditional asthma treatment approaches have been shown to either lack efficacy in preventing exacerbations requiring OCS or be associated with side effects (including modest effects on linear growth) in well-designed clinical trials, we explored potential alternative approaches that are currently being used by primary care physicians to gain new insights into therapeutic strategies that may warrant more systematic and objective evaluations. To our surprise, and despite a paucity of research on the efficacy of antibiotics for acute asthma episodes, oral antibiotics are frequently prescribed for wheezing illnesses in preschool children (~650 antibiotic prescriptions/1000 wheezing children)¹¹. Furthermore, recent data indicate that 28% of preschool children who make a physician visit for wheezing receive a prescription for an antibiotic within 2 days of the visit, and 77% receive a prescription for an antibiotic within 7 days. These prescriptions are dominated by azithromycin, which increased 15-fold between 1995 and 2001¹¹. These data suggest that physicians prescribe antibiotics frequently during respiratory tract illnesses, presumably due to concern for underlying bacterial infection, and those antibiotics appear to be prescribed both as a first line therapy early in the episode and, more frequently, concurrently with oral corticosteroids later in the episode.

The frequent use of antibiotics in these situations raises the question: is there something about the use of these medicines, and of azithromycin in particular, which reduces respiratory morbidity to the extent that it reinforces clinicians' behavior of prescribing them on such a frequent basis for children? A recent study in adult subjects provides some potential objective evidence to support the role of macrolide antibiotics during the early stages of asthma exacerbations. Administration of the ketolide telithromycin (a semisynthetic derivative of erythromycin) for 10 days to adults with asthma seen within the first 24 hours of acute asthma episodes resulted in significant improvements in symptom scores and lung function over the next 7 days relative to placebo¹². However, there was no relationship between bacteriologic status and the response to telithromycin treatment, suggesting a mechanism of action unrelated to the antimicrobial properties of telithromycin.

Are there reported effects of macrolide antibiotics that could explain a potential therapeutic effect in acute asthma and LRT episodes? Recent findings provide a plausible rationale. As a class,

macrolides have been demonstrated to provide clinical benefit in airway diseases such as cystic fibrosis¹³⁻¹⁶ and diffuse panbronchiolitis¹⁷⁻²⁰ possibly through mechanisms unrelated to direct antimicrobial activity. Viral infections, particularly caused by rhinovirus (RV), are associated with neutrophilic inflammation and increased IL-8 expression²¹⁻²³. Neutrophils are the predominant inflammatory cell at the onset of most infections²⁴, including those with rhinovirus²⁵, and although many chemo-attractants participate in summoning neutrophils to the site of infection, IL-8 seems to play a central role²³. Neutrophils are relatively insensitive to the therapeutic effects of corticosteroids²⁶, but interestingly, azithromycin has been demonstrated to attenuate immunoinflammatory responses, and may reduce the ensuing destructive neutrophilic inflammation. In addition, recent data demonstrated that azithromycin reduces RV replication and increases interferon gene expression in human bronchial epithelial cells²⁸. These effects may have substantial clinical relevance, as recent studies have demonstrated that primary bronchial epithelial cells from asthmatics have deficient *ex vivo* induction of interferon- β ²⁹ and interferon- λ after infection with rhinovirus³⁰, and the levels of IFN- λ were inversely related to severity of rhinovirus-induced asthma exacerbations in terms of decline in FEV₁ and viral load. These findings are especially important because, in children, viral infections are the major etiologic agent in episodes of clinically significant LRT symptoms³¹⁻³².

In summary, this trial examine the efficacy of a strategy for the challenging clinical problem of recurrent episodes of significant LRT symptoms. APRIL targets episode prevention through the early intervention with azithromycin prior to the onset of significant LRT symptoms. ***This trial will determine if this intervention can safely prevent such episodes, thereby lessening the morbidity of this common and difficult to treat problem.***

B. REVIEW OF CLINICAL TRIALS RELEVANT TO THIS PROTOCOL

MACROLIDE ANTIBIOTIC (AZITHROMYCIN)

Macrolides are bacteriostatic antibiotics that reversibly bind to 50S ribosomal subunit of susceptible microorganism and inhibit RNA-dependent protein synthesis. Over the past 30 years, macrolide antibiotics have been used to treat chronic inflammatory airway diseases based on their presumptive immunomodulatory activity⁴⁰.

MACROLIDES HAVE BENEFICIAL EFFECTS IN AIRWAY DISEASES SUCH AS CYSTIC FIBROSIS (CF) AND DIFFUSE PANBRONCHIOLITIS: Clinical trials in CF have documented significant improvement in lung function¹⁵ and quality of life parameters (e.g., weight gain) along with fewer exacerbations when using long-term azithromycin treatment^{14-16, 41}. Patients with CF are often colonized with *Pseudomonas aeruginosa*, an organism known to be resistant to the antimicrobial activity of macrolides. A meta-analysis that investigated the proposed anti-inflammatory effects in CF suggested that azithromycin improves lung function of CF patients, mainly in the subgroup of patients colonized with *Pseudomonas aeruginosa*⁴² and to a lesser degree in patients not colonized with this organism. However, a recent study investigated the effect of azithromycin on pulmonary function in patients with cystic fibrosis who were not infected with *Pseudomonas aeruginosa*, and revealed that while there was no effect on pulmonary function; patients treated with azithromycin

had significantly fewer exacerbations¹⁶. Therefore, it seems that the beneficial effects of macrolides in CF are distinct from their antibacterial effect.

Diffuse panbronchiolitis (DPB) is a chronic inflammatory disease of the respiratory bronchioles characterized by colonization with *Haemophilus influenzae* and/or *Streptococcus pneumoniae*, often with a change to *P. aeruginosa* over time. In the early 1980's, studies done in Japan revealed that erythromycin treatment dramatically improved survival in patients with DPB. Long-term, low-dosage erythromycin improved symptoms and increased 10-year survival from 12% to greater than 90% even in patients colonized with mucoid strains of *P. aeruginosa*¹⁷⁻¹⁹. Similar to the findings in CF, these beneficial effects do not appear to be mediated by the anti-bacterial activity of erythromycin.

The precise mechanism of action of macrolides in CF and DPB is unknown but thought to be due to an influence of macrolides on *P. aeruginosa* biofilms¹⁴ and to additional anti-inflammatory effects that will be discussed below.

Numerous trials have examined the potential efficacy of macrolides in asthma with variable results, including several studies demonstrating beneficial effects.^{12, 41, 43-52} However, a recent CARE Network trial was unable to demonstrate benefit in a group of children and adolescents with moderate to severe asthma (see below)⁵³. The above studies differ in their study designs, study populations, treatment protocols, and outcome measures, making generalization of the findings difficult. There is a long-standing debate whether these beneficial effects of macrolide in asthma are related to the antimicrobial activity of the macrolide against *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* (organisms which are known to promote asthma exacerbation and potentially contribute to asthma severity and/or persistence), or whether these agents have distinct additional anti-inflammatory effects. In order to review only studies that are relevant to this protocol, we will focus on studies that looked for differential response based on the infectious status of the patients or the type of the airway inflammation.

CHRONIC THERAPY WITH MACROLIDES TO IMPROVE ASTHMA CONTROL: Kraft et al. evaluated the role of clarithromycin in stable adult asthma patients with moderate - severe disease, with and without evidence of airway *Mycoplasma pneumoniae* or *Chlamydia pneumoniae*.⁴⁹ In this study, clarithromycin treatment for 6 weeks improved FEV₁ only in the sub -group of patients with evidence of infection. On the other hand, significant reductions were noted in BAL IL-12 and TNF- α mRNA expression that were not dependent on the bacteriologic status of the patient.

Strunk et al⁵³ investigated whether azithromycin (or montelukast) are inhaled corticosteroid sparing agents in children 6 to 17 years of age with moderate-severe persistent asthma. After a budesonide+salmeterol-stable period of 6 weeks, children were randomized to receive once-nightly azithromycin, montelukast, or matching placebos plus the established controlling dose of budesonide+salmeterol. The primary outcome was time from randomization to inadequate asthma control after sequential budesonide dose reductions. The study was terminated early due to randomization failure. A futility analysis revealed that azithromycin was unlikely to be effective as

an inhaled corticosteroid-sparing agent. This study differs significantly from the current protocol in several important ways: a different study population (preschool children with acute wheezing vs. school aged children with moderate –severe asthma), duration of therapy (5 days vs. continuous therapy for up to 30 weeks), and outcome measures (prevention of significant LRT symptoms vs. time to loss of asthma control during ICS reduction).

ACUTE THERAPY WITH MACROLIDES TO IMPROVE RECOVERY FROM ASTHMA EXACERBATION: A recent study in adults revealed that treatment with the ketolide telithromycin (a semisynthetic derivative of erythromycin) for 10 days in adults with asthma seen within the first 24 hours of acute asthma episodes resulted in significantly improved symptom scores and lung function over the next 7 days relative to placebo¹². In this study, there was no relationship between bacteriologic status and the response to telithromycin treatment. On the other hand, Fonseca-Aten et al⁵⁴ investigated whether clarithromycin started within 72 hours of the onset of acute wheezing episodes can affect inflammatory mediators' concentration in 28 children, 4-17 years old, with a history of recurrent wheezing or asthma (self-reported by the patient or caregiver). Clarithromycin treatment had no effect on clinical symptoms (dyspnea, cough, wheeze retraction, fever or clinical score) 3-5 days after initiation of treatment potentially related to the heterogeneity of patients' characteristics (age, underlying airway disorder), delay in initiation of treatment, or insufficient statistical power.

MACROLIDES HAVE *IN VIVO* EFFECTS ON MEASURES OF RESPIRATORY TRACT INFLAMMATION IN HUMANS: As noted above, while Fonseca-Aten et al⁵⁴ reported that clarithromycin given at the onset of acute wheezing episodes did not alter symptomatology, this therapy decreased inflammatory mediators' concentration, including TNF- α , IL-1 β , and IL-10 in nasal aspirates when measured 3-8 weeks after initiation of treatment. The effect was more profound in patients with evidence of *M. pneumoniae* or *C. pneumoniae* infection. These long-term immunologic effects suggest that macrolides may have long-lasting immunomodulatory effects even after therapy is completed. In another study in infants (1-7 months old) hospitalized with RSV bronchiolitis, daily clarithromycin treatment for 3 weeks resulted in significant reduction in plasma concentrations of IL-4, IL-8, and eotaxin while also reducing post viral recurrent wheezing episodes and improving the clinical course during hospitalization⁵⁵.

Taken together, many studies now strongly suggest that macrolides have anti-inflammatory mechanisms of action that are unrelated to their antimicrobial properties. One possible mechanism is attenuation of neutrophilic airway inflammation. Evidence for this was noted in a study by Simpson and coworkers: 8 weeks treatment with clarithromycin in adults with severe asthma resulted in reduced sputum concentration of IL-8 and neutrophil numbers and in improvement in quality of life scores⁵². More importantly, subgroup analyses revealed that these effects were driven by a subgroup of patients with neutrophilic asthma. This finding is highly relevant to our study since we anticipate a neutrophilic inflammation in our patients, as viruses are the major etiologic agents in episodes of significant LRT symptoms in children³¹⁻³² and viral infections, particularly caused by rhinovirus (RV), are associated with neutrophilic inflammation and increased IL-8 expression²¹⁻²³.

MACROLIDES HAVE ANTI-INFLAMMATORY EFFECTS IN *IN VIVO* ANIMAL MODELS OF AIRWAY

INFLAMMATION: Beigelman et al.⁵⁶ investigated whether azithromycin can attenuate allergic airway inflammation in a noninfectious mouse model of allergic asthma. In this model involving ovalbumin sensitization and challenge, azithromycin treatment resulted in a decreased number of leukocytes in the lung tissue and BAL fluid. In addition, azithromycin attenuated the expression of cytokines (e.g., interleukin IL-13 and IL-5) and chemokines (e.g., CCL2, CCL3, and CCL4) in the BAL fluid and abrogated the extent of mucous cell metaplasia. Two additional studies revealed beneficial effects of macrolides in 2 different animal models of viral lower respiratory tract infection. Sato et al investigated erythromycin treatment (Day 1 to Day 6 after the virus inoculation) using an *in vivo* mouse model of influenza pneumonia⁵⁷, while Beigelman et al⁵⁸ investigated azithromycin treatment (Day 1 to Day 7 after the virus inoculation) using an in-vivo mouse model of Sendai virus bronchiolitis. Both studies revealed that macrolide treatment resulted in attenuation of the course of acute disease evident by decreased weight loss, a decrease in leukocyte accumulation in the BAL, and reduced secretion of BAL inflammatory mediators. Of special interest is the finding that improved survival was independent of changes in viral load, i.e., although macrolide treatment enhanced resolution of airway inflammation, it did not prolong viral replication in the lungs.

MACROLIDES HAVE DIRECT *IN VITRO* ANTI-VIRAL VIRAL ACTIVITY: Gielen et al⁵⁹ investigated the potential anti-viral activity of macrolides in primary human bronchial epithelial cells. They found that azithromycin, but not erythromycin or telithromycin, significantly increased rhinovirus 1B-induced interferon production and interferon stimulated gene mRNA expression. Furthermore, azithromycin significantly reduced rhinovirus replication and release. Similar results were obtained in two additional *in vitro* models of human bronchial epithelial cells using clarithromycin for RSV⁶⁰ and influenza virus⁶¹ infection. These findings suggest that macrolide antibiotics may inhibit viral infection by mechanisms that are not related to their antibacterial properties. This is highly important and relevant to our study considering the major role of viruses in wheezing episodes in young children.

MACROLIDES HAVE *IN VITRO* ANTI-INFLAMMATORY PROPERTIES: Macrolides have been shown to inhibit neutrophil chemotaxis, leukocyte-epithelial cell adhesion, cytokine secretion, mucus production and cytokine-dependent intracellular signaling. Tsai et al⁶² demonstrated that azithromycin has a direct inhibitory effect on neutrophil chemotaxis that was mediated by decreasing the chemokine-dependent activation of the ERK-1/2 MAPK signaling pathways. In the *in vivo* part of their study, they suggested an additional mechanism mediating decreased neutrophil influx to the lungs. Using a murine model of mucoid *Pseudomonas aeruginosa* endobronchial infection, Tsai et al also demonstrated that azithromycin treatment resulted in decreased concentration of lung KC (CXCL1, the mouse homologue to human IL-8). The inhibitory effect of macrolides on IL-8 production was demonstrated in an additional study in which erythromycin and clarithromycin were shown to suppress mRNA levels and the release of IL-8 from normal bronchial epithelial cells as well as from main bronchi obtained from patients with chronic airway inflammatory diseases (asthma and DPB)⁶³. In regard to cell trafficking, roxithromycin pretreatment

of human neutrophils inhibited *in vitro* adhesion to human bronchial epithelial cells in association with a reduction of intercellular adhesion molecule expression on epithelial cells⁶⁴.

Mucus production is an additional characteristic seen in the inflamed asthmatic airway.

Clarithromycin and erythromycin inhibited mucus secretion from airway epithelial cells and this was associated with reduced MUC5AC mRNA expression⁶⁵. In an *in vivo* part of this study, oral administration of clarithromycin inhibited OVA- and LPS-induced mucus production and neutrophil infiltration⁶⁵. Other data show that macrolides may exert their anti-inflammatory effects by blocking NF-κB and or AP-1 dependent gene transcription of inflammatory mediators⁶⁶⁻⁶⁷.

In summary, the findings described above suggest that azithromycin may have the following *in vivo* and *in vitro* anti-inflammatory properties that might be beneficial in preventing and/or treating airway inflammation:

1. Direct anti-viral effects (*in vitro* studies).
2. Recruitment of neutrophils to the lungs:
 - a. Direct effect on chemotaxis (mouse model and *in vitro* studies).
 - b. Indirect effect on chemotaxis by reducing IL-8/ CXCL1 concentration (mouse model and *in vitro* studies).
 - c. Reduction of intercellular adhesion molecule expression on epithelial cells.
3. Secretion of cytokines and chemokines from inflammatory cells (human studies, mouse model and *in vitro* studies)
4. Mucus production (mouse model and *in vitro* studies).
5. Down regulation of inflammatory genes (*in vitro* studies).

C. SELECTION OF INTERVENTIONS FOR THIS TRIAL

APRIL: AZITHROMYCIN

We propose evaluating azithromycin, a member of the macrolide antibiotic family, as an early intervention modality. Three different forms of macrolides are FDA-approved for use in children in the US: erythromycin, clarithromycin, and azithromycin. All have been demonstrated to have anti-inflammatory and/or immunomodulatory effects (see section B). Erythromycin treatment is inconvenient since it needs to be given 3-4 times daily; therefore might result in poor compliance. In addition, it has significant gastrointestinal side effects that would limit its use in a pediatric trial. Clarithromycin has an inhibitory effect on the P450 enzyme system that metabolizes several drugs, including corticosteroids. Clarithromycin, like troleandomycin and erythromycin, is known to slow clearance of methylprednisolone (although not prednisolone)⁷³. This might complicate trial interpretation due to possible drug interaction with corticosteroid treatment and will not allow a definitive conclusion regarding the mechanisms of action of the medications. In addition, clarithromycin is administered twice daily and this might contribute to suboptimal adherence.

Azithromycin is a macrolide antibiotic which does not have the many of limitations discussed above. In contrast to the older macrolides, azithromycin does not interfere with the cytochrome P-450 complex liver enzyme systems that are responsible for metabolizing corticosteroids; therefore, it does not affect corticosteroid levels⁷⁴. Azithromycin has a very good safety and tolerability profile⁷⁵, and is currently one of the most commonly prescribed medications for acute wheezing episodes¹¹. From all of the above possibilities, we would expect better tolerability and adherence to azithromycin during the study than with the other available macrolides.

Azithromycin has a prolonged half-life, which allows for once daily administration. Following administration of azithromycin for 5 days, azithromycin could be detected in serum up to 72 hours after the final dose⁷⁶⁻⁷⁷. Moreover, the pharmacokinetics of azithromycin are characterized by rapid and extensive uptake within the intracellular compartment, with high and sustained antibiotic concentrations in tissues⁷⁸. This results in **effective anti-bacterial concentrations in the lung that have been detected more than 204 hours (about 9 days) after the last dose**⁷⁹. This prolonged accumulation in lung tissue will allow for determination of the efficacy of azithromycin administration during the entire episode, as pharmacologic activity will be present from the time of first administration (at the time of earliest symptom onset) to at least 9 days later.

We propose a double-blind placebo-controlled trial to examine the efficacy of azithromycin therapy relative to placebo in preventing progression of mild RTI to clinically significant LRT symptoms that require oral corticosteroids. The inclusion of a placebo arm is both ethical and necessary since no current safe intervention has been proven effective in preventing significant LRT symptoms.

D. RATIONALE FOR SELECTED STUDY POPULATION

The target study population is preschool aged children with recurrent episodes of significant lower respiratory tract symptoms for whom little evidence is available to direct therapy³ and thereby reduce the high levels of morbidity and health care utilization. The prevalence of self-reported 12-month or current asthma in the United States among the 0-4 year age group has increased dramatically over the past 2 decades, rising from 369,000 children in 1980 to 1,120,000 children in 2004⁸⁸, and approximately 65% of those children experienced an asthma attack within the past month. The preschool age group experiences significant morbidity related to asthma, as evidenced by 1,910,000 physician office visits for asthma, 336,000 emergency department visits, 120,200 hospitalizations, and 36 asthma deaths in 2004⁸⁸.

This study will enroll a cohort of preschool children with recurrent intermittent wheezing that has experienced at least one episode of recurrent clinically significant wheezing (defined as requiring OCS, ED visit, urgent care visit, and/or hospitalization) in the past year. Eligible children will have experienced any ONE of the following over the past year:

1. ≥ 3 episodes, ≥ 1 of which was clinically significant; **OR**
2. ≥ 2 clinically significant episodes; **OR**

3. Received ≥ 4 months of daily controller therapy AND experienced ≥ 1 clinically significant episode.

These features will identify children at high risk for continued morbidity associated with recurrent wheezing illnesses.

We anticipate that some children potentially eligible for this trial will have received regular controller medication for periods of time during the year prior to enrollment and thus, potentially have less symptomatic episodes as documented by the PEAK and other studies and recent EPR3 guidelines. To account for this decrease in wheezing episodes due to regular use of asthma controller medications, the requirement (#1 above) of at least 3 episodes of wheezing in the prior year will be reduced to (#3 above) at least 1 episode in patients who received regular asthma controller medication for at least 4 months during the year prior to enrollment. It is conservatively felt that 4 or more months of use of asthma controller medication might be expected to reduce the number of wheezing episodes by 1-2 episodes. Therefore, at least 4 months of controller medication will substitute for 2 of the 3 required wheezing episodes for patients on asthma controllers for at least 4 months during the prior year. This modification will not interfere with our intent to enroll children with histories of recent wheezing since these children will still have to have had at least 1 clinically significant episode in the year prior to enrollment. The requirement of 3 wheezing episodes in the year prior to enrollment will continue to be in effect for patients who have not been treated with asthma controllers for at least 4 months. Furthermore, children who have evidence of well-controlled symptoms immediately preceding study entry while receiving Step 2 controller therapy will have their controller therapy discontinued upon study entry. They will then have to demonstrate self-reported symptoms on average no more than 2 times per week and less than 2 nights per month of nocturnal awakenings, requiring albuterol, during the last 2 weeks of the 4-week period preceding the randomization visit in order to be eligible for randomization and not receive controller therapy during the trial.

We have chosen to include children irrespective of their subsequent asthma risk as determined by the Asthma Predictive Index^{2,89} for several reasons. Children with episodic wheeze form a heterogeneous group; some have risk factors associated with persistence of wheezing (i.e. persistent wheezers), while others experience a self-limited process (i.e. transient wheezers)⁹⁰. While some data are available to guide decision making in API positive children², there is an extreme paucity of evidence for API negative children. The PEAK trial informs the clinician of the benefits of daily ICS therapy in API+ children in terms of improving the proportion of episode free days and reducing exacerbations requiring OCS rescue, but exacerbations requiring OCS therapy did continue to occur with daily ICS therapy². In addition, daily ICS therapy was associated with a significant reduction in linear growth over the 2-year treatment period. The AIMS trial demonstrated that episodic ICS or LTRA therapy had modest effects on reduction in symptom severity in children with recurrent moderate-severe wheeze, but did not reduce exacerbations requiring oral corticosteroids⁴. While children in AIMS with positive API experienced greater symptom reduction than those with negative API, these interventions did not significantly alter the need for oral corticosteroids in either API positive or negative children. Thus, these 2 large CARE

Network trials of conventional asthma therapies in preschool children have not yet identified strategies for the consistent and complete prevention of exacerbations that do not have side effects. Based upon these gaps in knowledge, we propose to enroll preschool children with recurrent significant LRT symptoms irrespective of API status. However, we plan to examine the effects of the study interventions by API status to determine if there is a differential response to therapy by API status.

E. SELECTION OF STUDY MEDICATIONS, DOSAGES, AND DURATION

APRIL: AZITHROMYCIN DOSING STRATEGY: Azithromycin (12 mg/kg once daily for 5 days, maximum dose 500mg/day) or matching placebo will be administered to participating children at the first signs of onset of a respiratory tract illness. This dose is well within the safe dosing range for children as stated in the package insert and the PDR. Although the recommended dosages of azithromycin for acute otitis media, acute bacterial sinusitis, and community-acquired pneumonia are slightly less than what is proposed in this study (30 mg/kg as a single dose; 10 mg/kg once daily for 3 days; or 10 mg/kg as a single dose on the first day followed by 5 mg/kg once daily on days 2-5), 12 mg/kg/day is currently recommended for children with pharyngitis/tonsillitis due to an increased incidence of azithromycin-related treatment failure.

In a recent meta-analysis of nineteen randomized controlled trials⁹¹, azithromycin administered at 30 mg/kg per course for group A streptococcal pharyngitis was insufficient compared to 10-day courses of comparator antibiotics, including penicillin, erythromycin and clarithromycin. Whereas the 30 mg/kg course of azithromycin resulted in a 3-fold higher incidence of treatment failure, the 60 mg/kg course strongly favored azithromycin treatment.

Pharmacokinetic studies utilizing a lower dose of azithromycin (10 mg/kg day 1, 5 mg/kg days 2-5) in children 6-15 years of age (administered 1 hour before or 2 hours after meals) have reported detectable serum concentrations of azithromycin up to 72 hours after the final dose (**Figure 1**)⁷⁷. A similar study in children 7.5 months to 5 years of age with acute otitis media also observed a similar trend in serum azithromycin levels (**Figure 2**)⁷⁶. These trends are also apparent in the serum with higher 3-day dosing at 10 mg/kg/day and 20 mg/kg/day and are further mirrored in the tonsillar tissue (**Figure 3**)⁹². While 20 mg/kg/day of azithromycin given over three days is generally well tolerated by children, this dose is associated with slightly more adverse effects⁷⁵.




Figure 1. Plasma concentrations of azithromycin following the last 5 mg/kg dose in children 6-15 years of age. From ⁷⁷.




Figure 2. Plasma concentrations of azithromycin following the last 5 mg/kg dose in infants and preschool children 7.5 months to 5 years of age. From ⁷⁶.




Figure 3. Azithromycin concentrations in the plasma (A) and tonsillar tissue (B) in children treated with 10 mg/kg/day for 3 days (black squares) or 20 mg/kg/day for 3 days (black triangles). From ⁹².

According to the Zithromax[®] package insert, for the total azithromycin dosing regimen of 30 mg/kg, the most frequent side effects (occurring in $\geq 1\%$ of the subjects) were diarrhea, abdominal pain, vomiting, nausea and rash. The incidence of these side effects decreased substantially with 5-day dosing. For the dosage regimen of 12 mg/kg/day for five days proposed in this study (equivalent to 60 mg/kg total dose), similar side effects were seen in children, although the incidences were slightly greater (diarrhea: 5.4%; abdominal pain: 3.4%; vomiting: 5.6%; nausea: 1.8%; rash 0.7%; headache: 1.1%). No other treatment-related side effects occurred in pediatric patients with a frequency $>1\%$ (package insert).

A five-day course of azithromycin at 12 mg/kg/day as proposed in this study should ensure the desired anti-inflammatory and/or anti-microbial action(s) of the drug for a total of 10 days, while minimizing adverse effects. Azithromycin pharmacokinetics include rapid and extensive uptake within the intracellular compartment, with high and sustained antibiotic concentrations in tissues ⁷⁸, resulting in effective anti-bacterial concentrations in the lung that have been detected more than 204 hours (about 9 days) after the last dose ⁷⁹.

An azithromycin dose of 12 mg/kg/day for 5 days is well within the recommended dosage range for children and will further ensure sustained therapeutic levels in the respiratory tract, which is of primary interest and importance in this study. Given the uncertainty in optimal dosing to achieve anti-inflammatory and anti-viral activity, we propose using the highest approved dosing regimen (12mg/kg/day, maximum 500mg/day, for 5 days) to maximize the likelihood of achieving adequate and sustained azithromycin levels. Furthermore, since azithromycin's long biologic half-life results in 10 days of pharmacologic activity with 5 days of treatment, this property will allow for determination of the efficacy of azithromycin administration during the entire time of a respiratory tract illness episode, as pharmacologic activity will be present from the time of first administration (at the time of earliest symptom onset) to 10 days later. Thus, not only potential effects of azithromycin on the initial viral replication phase but also those on the subsequent neutrophilic inflammation will be tested in this trial.

F. PRIMARY OUTCOME MEASURES

The number of RTIs not progressing to APRIL/RTI Treatment Failure.

Treatment Failure for APRIL/RTI will be assigned if ANY of the following criteria are achieved:

- a. Having symptoms that are more than mild after 3 albuterol treatments* in 1 hour, **OR**
- b. Requiring albuterol treatment more than once every 4 hours**, **OR**
- c. Requiring more than 6 albuterol treatments over a 24 hour period, **OR**
- d. Having moderate-severe cough or wheeze for ≥ 5 days since APRIL therapy was initiated

* An albuterol treatment is a 2.5 mg albuterol by nebulization with facemask or 2 puffs of albuterol via MDI/spacer/mask.

** For the purpose of determining treatment frequency, on one occasion up to three albuterol treatments may be administered back-to-back and counted as a single treatment.

The goal of APRIL is to determine if the use of azithromycin initiated at the earliest sign of a respiratory tract illness is effective in preventing the progression of respiratory tract symptoms to a level of severity that would, in clinical practice, trigger the addition of an intervention, most typically oral corticosteroids. Thus, an outcome measure that accurately captures symptom progression to the level where a rescue intervention would routinely be recommended is necessary. The definition of Treatment Failure encompasses several clinical indicators. Parents will be educated as to the signs of episode progression and instructed to call the AsthmaNet center should this occur. During that phone contact, clinical status will be assessed by an AsthmaNet clinician, and if any of the Treatment Failure criteria are satisfied, the child will be immediately assigned APRIL treatment failure status. Thus, Treatment Failure will be determined in real time. We have chosen to use the number of episodes that do not progress on to Treatment Failure status instead of time from randomization to Treatment Failure because the participants are not at risk for Treatment Failure until an RTI occurs.

Once a participant meets the criteria for APRIL Treatment Failure, they will be started on a 4 day course of open-label corticosteroids. APRIL therapy will be continued for the full 5-day period even if the participant starts corticosteroids before the 5-day course of APRIL therapy is completed.

G. RATIONALE FOR GENETIC PREDICTOR ANALYSES

As explained earlier, IL-8 is a chemokine that plays a critical role in orchestrating neutrophilic inflammatory responses. There is evidence suggesting that a functional polymorphism in the IL-8 gene may increase susceptibility to lower respiratory illness and wheezing during viral infections in early life. Hull and coworkers¹⁰² showed that the A allele for a variant at position -251 in the promoter region of the IL-8 gene (IL-8/-251) was significantly more likely to be transmitted by their parents to children with RSV bronchiolitis than what would be expected by chance. This same group subsequently demonstrated that the A allele for IL-8/-251 was part of a haplotype that is associated with increased transcription rates for the IL-8 gene (Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility.¹⁰³ Moreover, they were able to show that, among children who had an episode of wheezing due to RSV in the first year of life and were still wheezing at a mean age of 6 years (“persistent wheezers”), the A allele was also more likely to be transmitted than what would be expected by chance¹⁰⁴. Of interest, the effect was much stronger for persistent wheezers who were not atopic than for those who were atopic.

These results thus suggest that IL-8/-251 may predispose for wheezing episodes associated with neutrophilic inflammation during the preschool years. We have postulated that azithromycin may prevent lower respiratory illnesses in children with recurrent wheezing by attenuating neutrophilic responses. It is thus plausible to surmise that a stronger preventive effect could be observed in carriers of the A allele for IL-8/-251, who are putatively more likely to show neutrophilic responses to viral infections, than in carriers of the T allele. This hypothesis will be tested as part of our secondary analyses in APRIL.

H. RATIONALE FOR RESPIRATORY VIRUS ANALYSES

Viral infections are the predominant trigger for acute episodes of wheezing in early childhood and represent a major cause of morbidity and severe exacerbations¹⁰⁵. The Childhood Origins of ASThma (COAST) high-risk birth (parental positive aeroallergen sensitization and/or history of parental asthma) cohort study has documented the importance of viruses during acute respiratory illnesses from birth to 3 years¹⁰⁶. Viruses were identified during wheezing episodes in 398 of 442 (90%) of these specimens. The types of viruses detected during the first 3 years of life included rhinovirus (212; 48%), RSV (93; 21%), parainfluenza (51; 12%), metapneumovirus (33; 7%), coronavirus (20; 5%), adenovirus (17; 4%), influenza (16; 4%), and enteroviruses (10; 2%). The importance of rhinoviruses in typical outpatient wheezing illnesses in 3 year olds in COAST extended earlier findings of the role of rhinoviral infection in the causation of 1/3 of hospitalized bronchiolitis

cases in infancy.¹⁰⁷⁻¹⁰⁸ Furthermore, identifying the type of virus causing the acute wheezing episode in young children may provide information related to prognosis and response to treatment. For example, infants who wheeze with rhinoviruses are at greater risk for recurrent wheezing¹⁰⁶ and asthma.¹⁰⁸⁻¹⁰⁹ In addition, treatment of infants with acute wheezing episodes with oral prednisolone reduced the incidence of recurrent wheeze if the initial illness was caused by a rhinovirus, but not RSV¹¹⁰.

Given the integral role played by respiratory viruses in wheezing episodes during early childhood, these studies offer an opportunity to further delineate the role of specific viruses in these episodes. Using convenient nasal sampling techniques and viral identification analyses mastered during COAST, we will obtain mucus at baseline and during each RTI with home sampling and analyze for respiratory viruses (see **Section V.S.5.**) during these RTI. These secondary analyses will attempt to characterize the following: (1) the distribution of viruses identified during each RTI in which intermittent therapy was begun, (2) the type of virus identified with the severity of the RTI, and (3) the type of virus with the response to azithromycin. These relationships should increase our knowledge of the role of viruses in wheezing episodes and their modification, if any, by treatment.

I. RESEARCH QUESTIONS

Among preschool-aged children with recurrent wheezing episodes and ≥ 1 clinically significant wheezing episode in the year prior to enrollment:

1. Is azithromycin, when administered at the initial and early signs of a respiratory tract illness more effective than placebo for preventing progression to clinically significant lower respiratory tract symptoms?

III. HYPOTHESES TO BE TESTED BY THESE TRIALS

A. PRIMARY HYPOTHESES

Among preschool-aged children with recurrent wheezing episodes and one or more clinically significant wheezing episode in the year prior to enrollment:

1. The risk of progression to clinically significant lower respiratory tract symptoms is lower if azithromycin is given at the early signs of an RTI compared with placebo. (APRIL - Prevention Trial)

B. SECONDARY AND EXPLORATORY HYPOTHESES

1. Compared to placebo, early administration of azithromycin will:
 - a. Reduce urgent care visits, ED visits and hospitalizations.

- b. Reduce measures of asthma-related symptoms during acute RTIs, including rescue albuterol use, absence from school, daycare, and/or parental work, and increase the measures of caregiver/patient quality of life.
- c. Not be associated with a greater rate of drug related side effects.
- d. Prolong the time to the 2nd and 3rd RTIs.
- e. Result in a lower rate of APRIL Treatment failure among participants who are carriers of the IL-8/-159 AA genotype, but not carriers of the other two IL-8/-159 genotypes than children of the same genotype who receive placebo.
- f. Reduce the rate of APRIL Treatment Failure among participants who experience an RTI due to infection with *Mycoplasma*, *Chlamydia*, or rhinovirus.

IV. STUDY PROTOCOL OVERVIEW AND DESIGN


APRIL is a randomized, double-blind, placebo controlled study in 600 preschool children 12-71 months with clinically significant wheezing episodes in the year prior to enrollment.

APRIL will compare azithromycin given for 5 days during the early signs of RTI to placebo directed at prevention of LRT symptoms (number of RTIs not progressing to treatment failure, primary outcome).

There will be a 2-4 week observation period to qualify and characterize the participants with respect to baseline demographic, atopic/asthma and genetic factors. The treatments for the 2 trials will be randomly assigned to one of the 4 treatment sequences (Figure 4). Participants may initiate APRIL therapy UP TO FOUR TIMES (i.e. experience up to 4 RTIs). Study participation is complete after 14 days of follow-up subsequent to starting open-label corticosteroids. For participants who do not meet APRIL study failure, study participation is complete after 14 days of follow-up subsequent to starting the fourth course of APRIL therapy. For participants who do not initiate a fourth course of APRIL therapy, study participation is complete after 78 weeks of follow-up from time of randomization.

Note: The APRIL protocol was originally designed as a 52-week study allowing participants to experience up to 3 respiratory tract illnesses instead of 4. The protocol was extended to 78 weeks in June 2012 because the North American 2011/2012 viral season was unusually mild and it was apparent that the power the APRIL study had been compromised due to the unexpectedly low rate of respiratory tract illnesses in the study population. At that time, approximately one-half of the study population had been enrolled. Of those, 60% were still in the original 52-week APRIL follow-up and 40% had completed the 52-week APRIL follow-up. All participants enrolled after the protocol change entered the 78-week follow-up period. Participants enrolled before the protocol change and still in the 52-week follow-up at the time of the protocol change were invited to join the 78-week follow-up and reconsented if they agreed. Participants who declined to join the 78-week follow-up were permitted to complete the 52-week follow-up under their original consent.

FIGURE 4: TRIAL DESIGN



V. PROTOCOL

A. STUDY GROUPS

We will randomize 600 children (67 children per clinical center) 12-71 months of age who meet all inclusion criteria and do not have any of the exclusion criteria. Children will be randomized in a 1:1 manner to one of the two APRIL treatment arms.

RUN-IN PERIOD: Participants who are not receiving long-term controller medications for asthma at Visit 1 will enter a two week run-in period. During this period, a two-week average will establish the presence of acceptable symptom control and will be calculated using the definition described below in **Section V.C.** below. Participants receiving step 2 NAEPP asthma guideline therapy (monotherapy with either low dose ICS or montelukast) will enter a four week run-in period during which time their asthma medication will be stopped at enrollment. The level of symptom control will be calculated during the last 2 weeks of the run-in period using the definition described below in **Section V.C.** below.

PATIENT IDENTIFICATION AND ENROLLMENT: Recruitment and enrollment will be performed over 18 months. Participants may be re-enrolled as specified below. For re-enrolled subjects, details for use of previous APRIL testing and questionnaires will be specified in the Protocol Manual of Operations (MOP).

B. INCLUSION CRITERIA

The following inclusion criteria pertain to APRIL. Participants who meet all of the following criteria are eligible for entry into APRIL. Participants may be reassessed if not initially eligible.

1. 12-71 months of age.
2. Recurrent significant wheezing in the past year (any of the following):
 - a. ≥ 3 episodes, ≥ 1 of which was clinically significant*; OR
 - b. ≥ 2 clinically significant* episodes; OR
 - c. ≥ 4 months of daily controller therapy AND ≥ 1 clinically significant* episode.*Clinically significant episode: requiring any of the following: (1) systemic corticosteroids (oral or injectable), (2) unscheduled physician office visit, (3) ED visit, (4) urgent care visit, or (5) hospitalization.
3. Up to date with immunizations, including varicella (unless the subject has already had clinical varicella). If the subject needs varicella vaccine, this will be arranged with the primary care physician and must be received prior to randomization.
4. Willingness to provide informed consent by the child's parent or guardian.

C. EXCLUSION CRITERIA

EXCLUSION CRITERIA AT SCREENING VISIT (V1):

Participants who meet any of the following criteria are NOT eligible for enrollment, but may be re-enrolled if these exclusion criteria are resolved:

1. >4 courses of systemic corticosteroids in past 12 months.
2. More than 1 hospitalization for wheezing illnesses within the preceding 12 months.
3. Use of long-term controller medications for asthma, including inhaled corticosteroids, leukotriene modifiers, cromolyn/nedocromil, or theophylline for more than 8 months (cumulative use) in the past 12 months.
4. Current use of **higher than step 2** NAEP asthma guideline therapy (e.g. medium-high dose ICS alone or combination therapy of low-medium-high dose ICS + LABA, montelukast, theophylline or cromolyn). NOTE: children who have evidence of well-controlled symptoms immediately preceding study entry while receiving Step 2 controller therapy (presence of self-reported symptoms on average no more than 2 times per week and less than 2 nights per month of nocturnal awakenings, requiring albuterol, during the 4 weeks preceding visit 1) may be enrolled and will have their controller therapy discontinued upon study entry.
5. Use of OCS in the past 2 weeks.
6. Daily symptoms or ≥ 2 nocturnal awakenings, requiring albuterol, in the last 2 weeks.

7. Use of antibiotics in the past month.
8. Current treatment with antibiotics for diagnosed sinus disease.
9. Participation presently or in the past month in another investigational drug trial.
10. Evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before trial completion.
11. Contraindication of use of systemic corticosteroids or azithromycin.
12. Clinically relevant gastroesophageal reflux.
13. Concurrent medical conditions other than asthma that are likely to require oral or injectable corticosteroids during the study.
14. If receiving allergy shots, change in dose within the past 3 months.

Participants who meet any of the following criteria are NOT eligible for enrollment, and may not be re-enrolled:

1. Gestation less than late preterm as defined as birth before 34 weeks gestational age.
2. Presence of lung disease other than asthma, such as cystic fibrosis and BPD. Evaluation during the screening process will assure that an adequate evaluation of other lung diseases has been performed.
3. Presence of other significant medical illnesses (cardiac, liver, gastrointestinal, endocrine) that would place the study subject at increased risk of participating in the study.
4. Immunodeficiency disorders.
5. History of respiratory failure requiring mechanical ventilation.
6. History of hypoxic seizure.
7. History of significant adverse reaction to any study medication ingredient.
8. The child has significant developmental delay/failure to thrive, defined as crossing of two major percentile lines during the last year for age and gender. If a child plots less than the 10th percentile for age and gender, a growth chart for the previous year will be obtained from the child's primary care provider.

EXCLUSION CRITERIA AT RANDOMIZATION VISIT

Participants will be ineligible for randomization if any of the following is documented, but may be re-enrolled if these exclusion criteria are resolved:

1. Persistent symptomatic asthma
 - a. For children who are controller naïve at the time of enrollment, persistent asthma is defined as asthma-related symptoms/albuterol use ≥ 4 days/week or ≥ 1 nighttime awakenings, requiring albuterol, on average during the 2 week run-in OR
 - b. For children who were receiving long-term controller medicine (low dose ICS or LTRA monotherapy) at the time of enrollment, persistent asthma is defined as asthma-related symptoms/albuterol use ≥ 4 days/week or ≥ 1 night awakenings, requiring albuterol, on-average during the last 2 weeks of the 4 week run-in

2. Inadequate adherence (< 80% of days) to diary card completion during the observation period.
3. Use of oral corticosteroids or antibiotics during the 2-4 week observation run-in.
4. Use of asthma medication except prn SABA during the 2-4 week observation run-in.

D. STUDY TREATMENTS

1. APRIL MEDICATIONS

Patients will be randomized at visit 2 to either azithromycin (Zithromax® 12 mg/kg once daily) or an appropriately matched placebo at the onset of the early signs of RTI, and this therapy will be continued for a total of 5 days. Participants will be treated for a maximum of 4 RTIs during the 78-week trial. During RTIs, all participants will receive albuterol inhalation treatments (2.5 mg albuterol by nebulization and facemask or 2 puffs of albuterol MDI with spacer and facemask) four times daily while awake (plus as needed) for the first 48 hours followed by albuterol by inhalation on an as needed basis. Criteria for starting APRIL therapy are outlined in **Section V.H.**

Note: The APRIL protocol was originally designed as a 52-week study allowing participants to experience up to 3 RTIs instead of 4. The protocol was extended to 78 weeks in June 2012. All participants enrolled after the protocol change entered the 78-week follow-up period. Participants enrolled before the protocol change and still in the 52-week follow-up at the time of the protocol change were invited to join the 78-week follow-up and reconsented. Participants who declined to join the 78-week follow-up were permitted to complete the 52-week follow-up under their original consent.

E. VISIT SPECIFIC PROCEDURES

Overall, there are 5 types of scheduled study visits or contacts as follows:

1. Enrollment Visit (V1).
2. Randomization visit (RZ) – 2-4 weeks following V1.
3. A Clinic visit that will occur 4 weeks following RZ (V3), and then subsequent follow-up visits every 8 weeks (V4, V5, V6, V7, V8, V9, V10, V11, V12).
4. Treatment telephone calls (PC) 4 weeks after each in clinic follow-up visit.
5. Study close-out visit (either V12) whichever of the following comes first:
 - a. 14 days after last dose of the fourth course of APRIL treatment.
 - b. 14 days after Study Failure (defined in detail in Section V.J.).
 - c. 78 weeks after randomization.

1. Enrollment visit 1 (V1), Week -4 to -2

- a. Appointment will be made for children aged 12-71 months with clinically significant wheezing episodes in the year prior to enrollment.
- b. Informed consent obtained.
- c. Eligibility determined based upon inclusion and exclusion criteria.
- d. Detailed allergy, asthma, and environmental questionnaires obtained.

- e. Medical history obtained.
- f. Physical examination including height and weight performed.
- g. An Action Plan provided and explained.
- h. Standard education about wheezing, use of the action plan, avoidance of allergens and irritants, will be discussed or provided at each visit starting at V1.
- i. Provide and teach Preschool Asthma Diary completion.
- j. If receiving long-term asthma controller medication, stop medication and discuss calling center if symptoms develop as outlined on the action plan.
- k. Dispense rescue medications (albuterol).
- l. Dispense nebulizer, if needed.

2. Randomization visit (RZ/V2), Week 0

- a. Diary cards reviewed.
- b. Inclusion and exclusion criteria reviewed.
- c. Informed consent reviewed.
- d. Brief history and physical exam including height and weight performed.
- e. Evaluate diary card adherence – participants must demonstrate at least 80% adherence to diary cards.
- f. Nasal mucus collecting technique for viruses will be demonstrated and collected for baseline determination of viruses. Supplies for home specimen collection will be dispensed with instructions.
- g. Blood sample for ImmunoCAP allergy testing of food and aeroallergens, IgE level, eosinophil count, and genetic analysis obtained.
- h. Serum/plasma saved for future studies.
- i. Action plan reviewed.
- j. Study drugs and rescue medications dispensed.

3. Follow-up visit during APRIL (V3, V4, V5, V6, V7, V8, V9, v10, v11) (V3 is 4 weeks after randomization, all other visits will be every 8 weeks)

- a. Diary cards reviewed.
- b. Brief history and physical exam including height and weight performed.
- c. Frozen nasal mucus samples collected and collection technique reviewed.
- d. Action plan reviewed.
- e. Study drugs and rescue medications dispensed.
- f. Diary cards dispensed.

4. Follow-up Phone Calls (PC) (4 weeks after each follow-up visit starting after V3)

- a. Parents will be called between post-randomization study visits to determine respiratory symptoms, albuterol use, and healthcare utilization within the preceding two weeks. These calls will help insure patient safety between scheduled study visits.

Study procedures action plan and medication adherence reviewed.

5. Study close-out visit (either V12 or APRIL FAILURE follow-up)

- a. Brief history and physical exam including height and weight performed.
- b. Quality of life questionnaires administered. (only for APRIL FAILURE follow-up, not for V12)
- c. Frozen nasal mucus samples collected.
- d. Nasal mucus sample will be collected for determination of viruses.
- e. Study drugs returned.
- f. Exit interview performed (critique of study experience; permission to be contacted for future studies).
- g. Treatment recommendations given.

F. OUTCOME VARIABLES

1. PRIMARY OUTCOME MEASURES

The number of RTIs not progressing to treatment failure – defined by criteria outlined in Section V.H.

Secondary Outcome Variables:

- a. Numbers of urgent care visits, ED visits, and hospitalizations.
- b. Rate of study failures during APRIL
- c. Measurements of disease impairment:
 - 1. Symptom severity and duration during acute RTIs
 - 2. Frequency of rescue albuterol use
 - 3. Absences from daycare and preschool for the child and work for the caregiver
 - 4. Measures of caregiver/patient quality of life.
- f. Rates of drug related side effects.
- g. Determine if demographic (sex, age) and baseline asthma/allergy phenotypic characteristics (API status, illness burden, family atopic history, individual components of the API, serum IgE level, blood eosinophil count, skin test sensitivity) will be associated with responsiveness to azithromycin.
- h. Pharmacogenetics, specifically the effect of IL-8/-159 AA genotype on response to APRIL therapy.
- i. Pharmacoeconomic impacts of APRIL therapy.

G. RANDOMIZATION

Patients who satisfy all the eligibility criteria at V1 and RZ will be randomized to study treatment arms of APRIL after all data collection has been completed. Treatment assignment will be performed according to a double-dummy, double-blind randomized parallel group design, with stratification by clinical center and age (12-41 months or 42-71 months). Study drug and rescue medications for APRIL will be dispensed.

H. CRITERIA FOR STARTING APRIL THERAPY

1. OVERVIEW OF HOME MANAGEMENT DURING ACUTE RTI

Parents will receive extensive education regarding close attention to development of symptoms that are likely to represent the early signs of an RTI with likely extension to associated chest symptoms. The parent is instructed to begin the APRIL study medication **as soon as the subject develops onset of the set of symptoms defined as the starting point for the child**, based upon the results of the Parental Respiratory Illness Questionnaire to detect of early warning signs of an exacerbation of lower respiratory disease as was used in AIMS and MIST (**APPENDIX 1**).

A formal written education module as used successfully during the AIMS and MIST trials will be provided to families to help them in identifying symptoms consistent with an RTI that is associated with a subsequent episode of LRT symptoms. Educational sessions involving the parent and AsthmaNet coordinator will take place at all study visits to ensure understanding of the terminology used to describe symptoms. This will allow parents to also identify symptoms and terms that they have used to describe their child's condition, as it is clear that not all parents and physicians use identical terminology.

2. CRITERIA FOR STARTING APRIL THERAPY DURING RTI

Defining treatment initiation criteria: The AIMS pilot study and clinical trial demonstrated that a specific Parental Respiratory Illness Questionnaire completed by parents was helpful in recognizing the specific symptoms experienced by their child that were indicators of an early RTI that would be predictive of a later wheezing episode. These subject-specific features will be used as the indicator to start APRIL study medications as was done in AIMS and MIST. The AIMS pilot study in twenty-eight parents of toddlers with histories of recurrent severe wheezing in the setting of RTI demonstrated that parents were able to identify a specific set of signs and symptoms that preceded and signaled the development of severe wheezing during a RTI. Ninety-two percent of parents reported a sign or symptom that made them feel very certain that the most recent RTI would lead to significant wheezing and 96% felt that the most recent episode was "typical" of what happens during an RTI that leads to wheezing. The most commonly reported first symptom categories during the first RTI were "nose symptoms" (41%), "significant cough" (29%), and "insignificant cough" (13%). The most reliable predictor of subsequent wheezing was significant cough, which had a specificity of 78% and a PPV of 74% for predicting wheezing. Overall, parents were confident in their ability to predict symptom progression for their child, and reported that this progression was typical. While most symptoms were chest-related, there were no individual symptoms that occurred in the majority of children. The utility of this method for initiating APRIL study treatment during RTI was confirmed in the AIMS trial. However, the questionnaire has been modified for APRIL by removing those symptoms associated with treatment failure in APRIL, as these would be inappropriately late signs to initiate APRIL therapy.

Initiating study treatment: Parents will be instructed to begin APRIL treatment during RTI based upon an individualized plan developed jointly by the parent and clinical center coordinator/physician at the first and second study visits in similar fashion to that used during AIMS and MIST. The plan will consider both the pattern of symptoms identified by the child's parent in the Parental Respiratory Illness Questionnaire that typically leads to episodes of LRT symptoms, as well as the clinician's judgment to promote as much consistency as possible and to avoid treating at the development of trivial symptoms. The subject-specific starting point will be based on the subject's previous history of symptom progression irrespective of whether symptoms originate in the upper or lower respiratory tracts. As noted in AIMS, this pattern is stereotypical for an individual child but highly variable among children¹¹¹. The AsthmaNet coordinator/physician will assure that the symptoms that trigger initiation of study medication meet the specific criteria identified in the parental survey.

At the first study visit, parents will be questioned as to the typical symptom progression during prior illnesses. The Modified AIMS/MIST Parental Respiratory Illness Questionnaire will be used (see **APPENDIX 1**). The parent will then be given the questions and list of possible symptoms to take home and reflect upon over the 2-week observation period. At the second study visit, the coordinator will again administer the Parental Respiratory Illness Questionnaire. The responses given on the second visit will be used to construct the individualized APRIL treatment plan for the trial. This approach will allow us to set a threshold level of symptoms prior to study medication use, but recognize that this threshold will be wide given the range of symptoms parents believe lead to symptom progression. Some parents may begin to detect symptoms at a relatively late stage of symptom development (this was seen occasionally in the parental survey). We will continue to work with families, especially those who tend to recognize symptoms relatively late, to help them identify symptoms at an earlier stage, thus allowing the most consistent early use of APRIL study medication. An education module with instructions as to when to start study medication modeled after the module successfully used in AIMS and MIST will be given to parents (**APPENDIX 2**).

As described above, the Azithromycin dosing strategy has been shown to have pharmacological activity for a total of 10 days and detectable levels in the lung for a total of 14 days. Parents will be instructed to contact the clinical center study team before beginning a new course of APRIL treatment if it has been less than 14 days since the last course was initiated. The clinical center study team will help the parent determine whether the current symptoms represent a new illness or a continuation of the previous illness.

3. AVAILABILITY OF ASTHMANET CLINICAL CENTER PERSONNEL: The AsthmaNet Clinical Center personnel or after-hours nurse triage center will be available for discussion with families 24 hours/day should uncertainty or questions arise on when to start APRIL study treatments. However, parents do not need to call the Clinical Center for permission to start APRIL medications, but they will be instructed to call the AsthmaNet clinical center or after-hours nurse triage center within 72 hours of initiation of study therapy to discuss the symptoms that prompted initiation of study medication and at any time should they have specific questions or concerns.

4. FAMILY INSTRUCTION TO CONTACT ASTHMANET CLINICAL CENTER DURING APRIL

- a. The family will be instructed and directed by an asthma action plan to call the AsthmaNet Clinical Center or after-hours nurse triage center if a prespecified frequency of albuterol used or significant symptoms develops in after starting APRIL (**APPENDIX 3**) and where upon open-label oral corticosteroid treatment might be initiated (outlined in detail in **Section V.I**).
- b. The parents will be instructed and directed by an asthma action plan to seek emergent care immediately if any symptoms requiring immediate medical attention such as severe respiratory distress or rapidly progressive symptoms occur and child will be directed to seek immediate medical care (either AsthmaNet Clinic, Urgent Care, or ED) (outlined in detail in **Section V.K**). Parents will be instructed to call the AsthmaNet Clinical Center or after-hours nurse triage center to inform the study personnel that emergency care was sought, after the child's status has improved.

We will continue to assess for criteria that indicate need for immediate medical attention at all contacts AND DIRECT THE FAMILY TO SEEK EMERGENCY CARE IF NOT ALREADY OBTAINED.

I. CRITERIA FOR STUDY TREATMENT FAILURE AND STARTING OPEN-LABEL CORTICOSTEROID TREATMENT

(**APPENDIX 4: STUDY TREATMENT FAILURE AND STARTING OPEN-LABEL CORTICOSTEROID TREATMENT FLOWCHART**).

1. STUDY FAILURE ASSIGNMENT. The family will be instructed and directed by an asthma action plan to call the AsthmaNet Clinical Center or after-hours nurse triage center when ANY of the following criteria signifying STUDY TREATMENT FAILURE are met:

- a. Having symptoms that are more than mild after 3 albuterol treatments* in 1 hour, **OR**
- b. Requiring albuterol treatment more than once every 4 hours**, **OR**
- c. Requiring more than 6 albuterol treatments over a 24 hour period, **OR**
- d. Having moderate-severe cough or wheeze for ≥ 5 days since APRIL therapy was initiated
- e. Symptoms requiring immediate medical attention (as outlined in section V.K.1.). **OR**
- f. There is an unscheduled visit for acute asthma care (physician office, urgent care, emergency department) with 1 albuterol treatment lasting more than 1 hour or more than one albuterol treatment (as outlined in section V.K.2), **OR**
- g. During an unscheduled visit for acute asthma care in a physician's office the child is transferred to urgent care or the emergency department due to severity of respiratory symptoms (as outlined in section V.K.2), **OR**
- h. Systemic steroids are needed for respiratory symptoms (as outlined in section V.K.2), **OR**
- i. Hospitalization is needed for asthma (as outlined in section V.K.3), **OR**
- j. Development of persistent symptoms ((as outlined in section V.K.4))

* An albuterol treatment is a 2.5 mg albuterol by nebulization with facemask or 2 puffs of albuterol via MDI/spacer/mask.

** For the purpose of determining treatment frequency, on one occasion up to three albuterol treatments may be administered back-to-back and counted as a single treatment.

***Prednisolone [2 mg/kg/day for 2 days (max 60 mg), followed by 1 mg/kg/day for 2 days (max 30 mg)].

If any of these STUDY Treatment Failure criteria are met, the AsthmaNet Clinical Center personnel or after-hours nurse triage center will assign the child STUDY Treatment Failure and advise the family to start the child on OPEN-LABEL CORTICOSTEROID TREATMENT [2 mg/kg/day for 2 days (max 60 mg), followed by 1 mg/kg/day for 2 days (max 30 mg)] immediately if not already started. The AsthmaNet Clinical Center personnel or after-hours nurse triage center will document if child used APRIL therapy and for how long.

Physician discretion can be used to assign STUDY Treatment Failure and initiate OPEN-LABEL CORTICOSTEROID TREATMENT if it is deemed to be in the best interest of the child, even if none of the specific criteria above are met. However, if physician discretion is used, the AsthmaNet Clinical Center personnel will document the rationale for the decision.

The AsthmaNet Clinical center personnel or after-hours nurse triage center will schedule a follow-up call for safety in 1 and 24 hrs and an appointment will be scheduled in the AsthmaNet clinical center for a STUDY FAILURE follow-up visit within 2 weeks or within 72 hrs if the child required urgent medical attention. The AsthmaNet Clinical Center personnel or after-hours nurse triage center will remind the family to give the child albuterol treatments every 4 hrs and call the clinical center if the respiratory symptoms worsen (as outlined in section V.I.2).

After-hours nursing triage center: To ensure consistent assignment of STUDY treatment failure and to have immediate access to personnel familiar with APRIL study protocols, 24 hours a day, 7 days a week, an after-hour nursing triage center will be available for calls placed to the AsthmaNet Clinical Center during the night, holidays and weekends. The family will be instructed on their asthma action plan when to contact the AsthmaNet Clinical Center and the after-hours nursing triage center. The families will be instructed to use a 1-800 triage number that identifies that the caller is part of the APRIL study. The after-hours triage nurse is a RN trained in APRIL protocol and algorithms in a similar manner to the AsthmaNet study coordinators. The nurses will have ready access to a computerized set of telephone algorithms for APRIL and the AsthmaNet center's study personnel coverage information. These protocols will allow him/her to direct the patient to the appropriate care for his or her situation that may include starting study medication or advising the family to take the child to the Emergency Room. The triage nurse will also contact the study coordinators and physicians in a timely manner to inform them of your child's situation, need for further evaluation and/or scheduling of a STUDY FAILURE follow-up visit. There will always be on call study personnel available to the triage nurse at each AsthmaNet clinical center 24 hours a day. A written report of the call will be sent to the AsthmaNet Clinical Center where the patient was enrolled.

2. FAMILY INSTRUCTION TO CONTACT ASTHMANET CLINICAL CENTER ONCE OPEN-LABEL CORTICOSTEROIDS ARE INITIATED

- a. The family will be instructed and directed by an asthma action plan to call the AsthmaNet Clinical Center or after-hours nurse triage center if specific frequency of albuterol used or significant symptoms develops in after starting OPEN-LABEL CORTICOSTEROID TREATMENT to help them determine if urgent care is needed (outlined in detail in Section V.J).
- b. The parents will be instructed and directed by an asthma action plan at any time during the study to seek emergent care immediately if any symptoms requiring immediate medical attention such as severe respiratory distress or rapidly progressive symptoms occur and child will be directed to seek immediate medical care (either AsthmaNet Clinic, Urgent Care, or ED) (outlined in detail in Section V.K.1). Parents will be instructed to call the AsthmaNet Clinical Center or after-hours nurse triage center to inform the study personnel that emergency care was sought, after the child's status has improved.

We will continue to assess for criteria that indicate need for immediate medical attention at all contacts AND DIRECT THE FAMILY TO SEEK EMERGENCY CARE IF NOT ALREADY OBTAINED.

**J. CRITERIA FOR URGENT MEDICAL EVALUATION DURING OPEN-LABEL CORTICOSTEROIDS TREATMENT DURING STUDY FAILURE
(APPENDIX 4: STUDY TREATMENT FAILURE FLOWCHART)**

The family will be instructed and directed by an asthma action plan to call the AsthmaNet Clinical Center or after-hours nurse triage center when a pre-specified set of significant symptoms develops after starting **OPEN-LABEL CORTICOSTEROID TREATMENT** (outlined in detail in **Section V.K**).

If these criteria are met, the AsthmaNet Clinical Center personnel or after-hours nurse triage center refer the child for urgent medical evaluation.

K. SYMPTOMS REQUIRING UNSCHEDULED VISITS OR IMMEDIATE MEDICAL ATTENTION AT ANYTIME DURING THE STUDY

1. Parents will be instructed and directed by an asthma action plan to seek emergent care immediately if any severe respiratory distress or rapidly progressive symptoms occur in either APRIL or OCELOT at any time during the study.. Criteria for immediate evaluation include any of the following:

- a. Severe respiratory distress, including (but not limited to) nasal flaring, retractions not immediately responsive to bronchodilator, altered level of consciousness
- b. Cyanosis
- c. Signs of dehydration
- d. Rapidly progressive symptoms

Parents will be instructed to call the AsthmaNet Clinical Center or after-hours nurse triage center to inform the study personnel that emergency care was sought, after the child's status has improved. If

the AsthmaNet center or after-hours nurse triage center confirms the occurrence of any of these criteria (a-d), Study Failure status will be assigned and the child will be directed to seek immediate medical care (AsthmaNet Clinic, Urgent Care, or ED). In any scenario outlined above, the child will be evaluated by AsthmaNet Clinical Center personnel within 72 hours. The AsthmaNet personnel will also call the family to set up a final study visit and will document if the child used APRIL therapy and for how long. A 5-day course of open label OCS will be considered per the AsthmaNet Clinical center's physician discretion.

2. CRITERIA FOR THE RESCUE TREATMENT OF A CHILD WITH AN UNSCHEDULED VISIT FOR ACUTE EXACERBATIONS OF WHEEZING/LRTI

Any child seen in a physician's office, emergency department or urgent care for persistent respiratory symptoms (more than mild in degree) requiring at least 3 repeated (or continuous) albuterol treatments, systemic corticosteroid treatment, or transfer from a physician's office to urgent care or the emergency department due to severity of respiratory symptoms will be evaluated by AsthmaNet clinic personnel within 72 hrs and then in 1-2 weeks for a final study visit. Blinded study participation will be discontinued. For those children that did not receive open-label OCS in the physician's office, emergency department, or urgent care, a 4-day course of open-label OCS will be considered per the AsthmaNet Clinical center's physician discretion. The family will be asked to call the clinic back if the symptoms do not improve or worsen. Per the physician's discretion, the family may be provided with a 6-week supply of open-label inhaled corticosteroids. Communication regarding this study visit and any prescribed medications will be sent to the child's primary care provider. If the symptoms do not improve or worsen, the child will be evaluated by AsthmaNet clinic personnel (safety visit) or referred to urgent care or ED if symptoms severe. A second course of open-label oral corticosteroids will be considered.

Two-weeks after the AsthmaNet Clinical Center visit, the family will be called by the AsthmaNet center personnel for a safety follow-up. Clinic coordinators will ask the parents at the two-week call if they have contacted the child's primary care provider. Coordinators will emphasize the importance of contacting the child's primary care provider for further treatment; both at the final study treatment failure visit and at the two-week follow up phone call.

3. CRITERIA FOR THE RESCUE TREATMENT OF A CHILD WITH HOSPITALIZATION FOR ACUTE EXACERBATIONS OF WHEEZING/LRTI

If the child is hospitalized during the study for an acute exacerbation, the NAEPP Guidelines for the in-hospital treatment of asthma will be followed. During hospitalization and upon discharge, the child will be treated per physician discretion.

The child will be evaluated by AsthmaNet clinic personnel within 72 hrs and then in 2 weeks for a final study visit. The child will be assigned STUDY FAILURE STATUS. Blinded study participation will be discontinued. If the child did not receive open-label OCS on discharge, a 4-day course of open-label OCS will be considered per the AsthmaNet Clinical center's physician discretion. The family will

be asked to call the clinic back if the symptoms do not improve or worsen. Per the physician's discretion, the family may be provided with a 6-week supply of open-label inhaled corticosteroids. Communication regarding this study visit and any prescribed medications will be sent to the child's primary care provider. If the symptoms do not improve or worsen, the child will be evaluated by AsthmaNet clinic personnel (safety visit) or referred to urgent care or ED if symptoms severe. A second course of open-label oral corticosteroids will be considered.

4. CRITERIA FOR THE RESCUE TREATMENT OF A CHILD WITH SIGNIFICANT PERSISTENT ASTHMA SYMPTOMS

During scheduled study visits and routine phone calls, the frequency of asthma-like symptoms will be determined. Significant Persistent Asthma will be defined as daytime symptoms of cough or wheeze which on average 5 or more days a week on average over the past 4 weeks or if nighttime symptoms of cough and wheeze that wake the child up and occur at least once a week on average over the past 4 weeks.

If symptoms have persisted for at least 4 weeks, the child will be seen in the AsthmaNet clinical center and evaluated for an alternative diagnosis for ongoing symptoms (such as sinusitis). If a diagnosis other than persistent asthma, such as sinusitis, is established, treatment of that condition may be prescribed (such as a course of oral antibiotics other than a macrolide) and the child reassessed after completion of treatment. If symptoms do not resolve with this therapy, or if an alternative diagnosis is not established, the child will be assigned STUDY FAILURE STATUS. Blinded study participation will be discontinued. A 4-day course of OCS will be considered per the AsthmaNet Clinical Center's physician discretion. The family will be asked to call the clinic back if the symptoms do not improve or worsen. Per the physician's discretion, the family may be provided with a 6-week supply of open-label inhaled corticosteroids. Communication regarding this study visit and any prescribed medications will be sent to the child's primary care provider. If the symptoms do not improve or worsen, the child will be evaluated by AsthmaNet clinic personnel (safety visit) or referred to urgent care or ED if symptoms severe. A second course of open label oral corticosteroids will be considered. The family will be seen in the AsthmaNet clinic center in 1-2 weeks after the STUDY FAILURE STATUS ASSIGNMENT for a final study visit. Two-weeks after the AsthmaNet Clinical Center visit, the family will be called by the AsthmaNet center personnel for a safety follow-up. Clinic coordinators will ask the parents at the two-week call if they have contacted the child's primary care provider. Coordinators will emphasize the importance of contacting the child's primary care provider for further treatment; both at the treatment failure visit and at the two-week follow up phone call.

L. NON-STUDY DRUGS

Other drugs considered necessary for the child's welfare may be given, although these will be recorded specifically. Antibiotics, inhaled corticosteroids, systemic corticosteroids, and albuterol should only be used as outlined in the protocol unless by physician discretion and discussed with the

coordinating center. Antibiotics other than macrolides may be prescribed for suspected or confirmed bacterial infections for the minimal duration necessary.

M. RECRUITMENT

Each clinical center involved in the AsthmaNet was chosen, in part, based on documentation for participant availability in clinical trials with similar entry criteria. Each center will randomize 67 study patients. Satellite clinics may be established for some or all of the AsthmaNet Clinical Centers to aid in recruitment. The specific plans for recruitment at each center are summarized **APPENDIX 5**.

N. DRUG SUPPLIES

Azithromycin Dry Powder for Oral Suspension (200 mg/5 ml) from Teva Pharmaceuticals, Inc. (NDC 0093-2026-31) and corresponding placebo will be used for the APRIL portion of the study. The AsthmaNet Data Coordinating Center contracted with Bilcare Global Clinical Supplies to develop and manufacture a matching placebo and to distribute blinded drug supply to the clinical centers.

FOR STUDY FAILURE ORAL CORTICOSTEROID TREATMENT: Prednisolone Oral Solution (15 mg/5ml) [2mg/kg/day for 2 days (max 60mg), followed by 1mg/kg/day for 2 days (max 30 mg)] will be used..

Albuterol sulfate will be used as a rescue during the APRIL study (inhalation solution, 0.083%, pre-mixed 2.5mg/3ml, 30x3ml, Nephron Pharmaceuticals or inhalation aerosol, Ventolin, 18g, 200 metered inhalations, 90mcg per actuation). Albuterol will be purchased and distributed to the clinical centers by the Investigational Pharmacy at the Milton S. Hershey Medical Center.

O. ADHERENCE

As much as possible, use of study medications will be monitored to enhance patient adherence. Volumes of remaining prednisolone will be measured at each visit. Adherence assessment of the azithromycin vs. placebo will be based upon volume remaining.

P. EDUCATION

Standardized education about the management of RTI will focus on early recognition of signs of lower respiratory tract involvement that are highly likely to progress to clinically significant lower respiratory tract episode. These materials have been successfully used in CARE Network studies (AIMS and MIST). We will use supplemental information specific to RTI-induced symptoms, the use of the nebulizer and a metered dose inhaler with valved holding chambers.

Q. RETENTION

Since this is a relatively short-term study, retention efforts will focus on ease of visits and informational rewards (such as the asthma education). Visits will be at times convenient to the parents, many of whom work (thus, hours after day care and preschool will be available). We will

make every effort to minimize parking problems and other general inconveniences. A monetary incentive will be given for each visit, with a bonus at the end of the study for completion of all visits. Study staff will be available to answer questions about asthma and how to use the action protocol. A study physician will be available by phone during off-hours to aid in management of wheezing illnesses.

R. MONITORING FOR ADVERSE EFFECTS OF TREATMENT

Nasopharyngeal surveillance culture for antibiotic resistance among *S. pneumonia* and upper respiratory tract flora

It has been suggested that long-acting macrolides such as azithromycin would select resistance more effectively than other macrolides¹¹²⁻¹¹³. This has been demonstrated in a number of studies where increased outpatient antimicrobial consumption of azithromycin is connected to increased antimicrobial resistance in *s. pneumoniae*¹¹⁴⁻¹¹⁷. Thus, widespread use of this antibiotic for prevention of LRT symptoms may promote antimicrobial resistance. To screen for this possibility, we plan to obtain a nasopharyngeal sample and perform a culture and susceptibility testing only at the St. Louis AsthmaNet Clinical Center. Culturing of organisms on Columbia CNA agar, which contains 5% sheep blood and Colistin and Nalidixic Acid to select for Gram-positive organisms, and 4mcg/ml azithromycin. This will be obtained at 3 time points:

1. The first sample will be collected at the randomization visit (V2).
2. The second samples will be collected during a follow-up visit after the first course of APRIL therapy ; these samples will be obtained if the visit occur after a minimum of 14 days from the last dose of APRIL therapy (otherwise, it will be obtained at the next visit).
3. The third and final sample will be collected at the study close out visit, a minimum of 14 days after the last dose of APRIL therapy.

The objective of this surveillance protocol is to determine if an increased prevalence of resistant *S. pneumoniae* and upper airway flora is associated with the number of APRIL courses. The AsthmaNet clinical center personnel will record if the child used any open-label antibiotic therapy in the past 2 weeks. This study will be performed on participants from the St. Louis center only.

Length/Height and Weight

Height will be measured with a standard calibrated stadiometer with addition of a backboard to assure good posture (the standard stadiometer has a board that is not long enough for younger children). Children 1-2 years of age will have body length measured using an infant stadiometer. Children older than 2 years will have standing height measured with a standard calibrated stadiometer as detailed in the AsthmaNet MOP. Height will be measured at every visit and plotted on a growth chart appropriate for age and gender.

S. SPECIAL STUDY TECHNIQUES

1. **Definition of phenotype of wheezing:** The phenotype of wheezing will be described for those factors noted in PEAK that were related to ICS responsiveness, including age, previous morbidity as

reflected by number of urgent care/ED visits and hospitalizations, medication use and asthma symptoms, family and personal history of atopic disease, ImmunoCAP for allergy, total blood IgE, and eosinophil counts. Standard questionnaires derived from AsthmaNet materials will be used. IgE will be determined and peripheral blood will be analyzed for CBC with differential and total eosinophil counts.

2. Genetic Analysis: Blood will be obtained at the study sites from the participant and processed at the laboratory of Dr. Fernando Martinez at the Tucson AsthmaNet site. We will also collect buffy coat cells to assess intermediate phenotypes relating CD14-159 genes to their direct products or to other intermediate steps linking the gene (and its variants) to asthma since this will allow us to assess phenotypes that are closer in the causal pathway to the CD14-159 gene. The buffy coat will be separated after blood collection, placed in adequate medium, and frozen immediately and stored in liquid nitrogen or in at least a -70°C freezer. The genetics analysis procedure is modified from that applied to the Asthma Clinical Research Network and Childhood Asthma Research and Education Network protocols and detailed in the AsthmaNet Manual of Operations. Specific policies and procedures have been developed to maintain confidentiality of samples with special coding to remove all patient name identifiers. A certificate of confidentiality will be obtained from the NHLBI. Genetics analyses will be limited to those related to drug response, drug metabolism, allergy, asthma and inflammation. A separate protocol will be developed that will prioritize genetic analysis for this study. Dr. Fernando Martinez will lead the Committee from the AsthmaNet Genetics Laboratory. The procedures for blood and buffy coat collection, storage, and shipping will be operationalized in the MOP. The genetics sections in the consent form will follow the templates used successfully in our prior ACRN and CARE protocol consent forms for explaining the purpose of the genetic analyses and for protecting the genetic rights of the subjects involved in this study. We will include a provision in the consent that will state that we will contact the families after this study is completed if future genetic studies are proposed.

3. Allergy *in vitro* testing: An ImmunoCAP {Phadia} allergen-specific IgE will be assessed for the following allergens will be performed at a central laboratory (St. Louis Children's Hospital).

#	Allergen class	ImmunoCAP code	Allergen content
1	Cat	e1	Cat dander
2	Dog	E5	Dog dander
3	Mouse	E72	Mouse urine proteins
4	Mold mix	Mx1	Penicillium chrysogenum, Cladosporium herbarum, Aspergillus fumigates, Alternaria anternata
5	Cockroach (German)	i6	Blatella germanica
6	Grass mix	gx2	Bermuda, rye, Timothy, Kentucky bluegrass, Johnson, Bahia
7	Tree mix	Tx4	Oak, elm, maple, willow, cottonwood
8	Tree mix	Tx6	Box-elder, birch, beech, oak, walnut

9	Weed mix	Wx1	Common ragweed, mugwort, plantain, lamb's quarter, Russian thistle
10	Weed mix	W3	Giant ragweed
11	Mite	D2	D. farinae
12	Mite	D1	D. pteronyssinus
13	Cow's milk	F2	Cow's milk
14	Egg white	F1	Egg white
15	Peanut	F13	Peanut
16	Rat	E74	Rat urine protein

4. Quality of Life Assessment: The "The Effects of a Young Child's Asthma Flare-Up on Parents" is a 23-item questionnaire developed according to the standardized procedures of item generation with 100 caregivers of acute ill asthmatic children; item reduction, again with another set of 100 caregivers; item presentation and scaling with another set of about 20 caregivers; and finally testing for psychometric properties which was done in the context of the *Pre-emptive use of High-Dose Fluticasone for viral-induced asthma in preschool-aged children: a randomized controlled trial*.¹¹¹ Permission to use this copyrighted questionnaire has been secured and the instrument is included in the Manual of Operations.

5. Nasal Sampling Technique: Collection of nasal samples. For the collection of nasal mucus for diagnostic virology, parents will have the option of using one of two procedures: nasal swab or the "nose-blowing technique". The choice will depend on the age of the child and the child's preference. Both collection techniques, nasal swab and nasal blowing, were implemented in the CARE network MIST study with a high level of acceptance by the family and an equivalent viral detection rate during exacerbations (84% and 86%, respectively). Either type of specimen is amenable to the PCR-based viral diagnostics as described below. Nasal swabs will be collected as described by the Finnish group¹¹⁹. The nose blowing technique will be used for any child that is able and willing to perform this maneuver. We have developed an illustrated flyer to teach this procedure to parents and children participating in the study. Nasal secretions are collected at the beginning of the study, and during each respiratory illness that meets the criteria outlined in the main protocol. The "nasal blow" procedure will be taught and collected at the RZ visit, and materials will be distributed to the homes for collection with each RTI. In addition, a clinic nasal sample for viruses will be done at the final visit. Briefly, participants spray saline into one nostril, occlude the other one, and then blow the nose into a "baggie". The procedure is repeated on the other side. 2 ml of a solution containing buffered saline (pH 7.4) along with 0.5% gelatin is then added to the baggie, which is then sealed and placed into a container in the freezer. To model effects of storage conditions on HRV detection, we conducted preliminary experiments in which samples of low-dose HRV (102 particles per sample) were stored in Ziploc bags in the saline/gelatin mix at either room temperature, 4°C, or -20°C. Specimens in the refrigerator or freezer did not lose signal in our PCR-based diagnostic assays for at least 5 weeks (which was the duration of the test). In fact, samples

left out on the tabletop for up to 4 weeks without refrigeration still tested positive. Respiratory multicode assay (RMA) is a high throughput and sensitive multiplex PCR based on unique chemistry (Multicode, EraGen Biosciences). The assay detects the following viruses: HRV, enteroviruses, coronaviruses (including OC43, 229, NL63, HKU1), adenoviruses B, C, and E, influenza A and B, parainfluenza viruses I-IV, RSV A and B, metapneumovirus, and bocavirus. In the MIST study, approximately 90% of the MIST exacerbations were associated one or more of these viruses using these methods of detection. Detection of *M. pneumoniae* and *C. pneumoniae* in upper airway samples by PCR technology will also be done.

6. Blood Samples: Blood (serum) will be collected and stored for future analyses of biomarkers that are considered directly relevant to any genetic polymorphisms related to asthma and allergies that are found following the genetic analyses. This will provide a means to assess whether certain asthma and allergy genes have the potential of increasing or decreasing proteins in sera to gain new insights into pathophysiological mechanisms underlying these diseases.

7. Diary card: The validated Preschool Asthma Diary¹²¹ will be used to record participant symptoms during respiratory tract illnesses. The diary includes six symptom categories (cough, wheeze, sleep disturbance, lethargy, appetite, irritability and response to albuterol response), each scored on a one through seven scale.

T. RISKS/BENEFITS

APRIL compares the effect of azithromycin to placebo at the onset of RTI in young children who have experienced morbidity due to similar episodes the preceding year. The inclusion criteria require that all participants have experienced enough significant episodes previously to expect a similar pattern of illness the following year. All children in the trial will receive inhaled bronchodilators during the course of RTI and for rescue. All children will have action plans available, AsthmaNet physicians availability 24 hours a day for guidance.

The performance of a trial in children with severe intermittent asthma with a history of significant exacerbations increases the likelihood of hospitalization during this trial. While we anticipate a reduction in episode severity compared to previous episodes, children enrolled in this trial may develop wheezing episodes of sufficient severity to require inpatient care. Hospitalization will be considered a Serious Adverse Event, and be reported to local IRBs and the AsthmaNet DSMB in the usual manner. Furthermore, hospitalization for asthma is a criterion for treatment failure, at which point the child will be removed from the blinded treatment phase.

Potential risks in this trial include side effects from any of the medications administered. All medications used in this trial have been demonstrated to be safe and are FDA-approved for the age group studied.

Criteria are established for patients who are having ongoing problems related to wheezing (**Section V.K.d.**). Potential benefits from participation include intensive education and support for the

management of wheezing illnesses as well as the potential benefit of the study interventions resulting in less severe wheezing illnesses and less child and family morbidity.

U. ANTICIPATED RESULTS

The purpose of APRIL is to provide definitive evidence regarding the potential use of azithromycin at the earliest signs of RTI to prevent progression to clinically significant LRT episodes and use of OCS in preschool children. It is anticipated that treatment with azithromycin at the onset of RTI will be associated with a lower rate of episode progression relative to placebo. However, either a negative or a positive result would provide important new information to guide therapy. If the trial fails to show any positive effect of azithromycin, there will be no justification for the frequent use of this antibiotic in young children with recurrent wheeze. Thus, promoting less use of this antibiotic during wheezing episodes will have a positive impact on anti-microbial resistance. If azithromycin is effective in reducing LRT symptoms, we would have identified the first therapeutic approach with clearly demonstrated capacity to prevent severe LRT episodes in preschool children.

Finally, secondary analyses should add to our understanding of the relationship of asthma phenotype and genotype to azithromycin responsiveness and the relationship of respiratory viruses to asthma exacerbations and responsiveness to study treatments.

VI. ADVERSE EVENTS

A. DEFINITION OF AN ADVERSE EVENT

An adverse event (AE) shall be considered any detrimental change in the patient's condition whether it is related to an exacerbation of asthma or to another unrelated illness. The International Conference on Harmonization (ICH) guidelines further define an AE as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product regardless of its causal relationship to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product. The occurrence of an AE may come to the attention of study personnel during study visits or telephone interviews or by a patient presenting for medical care. Unanticipated AEs and severe adverse events (SAEs) will adhere to federal and local IRB reporting mandates as well as ICH Guidelines for Good Clinical Practice.

B. APRIL: MONITORING OF ADVERSE EVENTS RELATED TO AZITHROMYCIN

Azithromycin is a macrolide antibiotic derived from erythromycin. Azithromycin has a wide distribution throughout all body tissues and is identifiable in the airway sputum within 2-4 hours after oral administration. Peak serum concentrations of azithromycin increase slightly when administered with food and decrease somewhat with co-administration of antacids containing aluminum and magnesium hydroxide. While azithromycin does not have to be taken with food or milk, parents will be instructed to avoid concomitant administration of antacids.

Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, and any macrolide or ketolide antibiotic. Although azithromycin is well tolerated in children, some side effects have been reported. In clinical trials of 5-day dosing in children, the incidence of treatment-related adverse events was 9%. The most common side effects were diarrhea or loose stools (4%), vomiting (2%), and abdominal pain (2%). A similar incidence of treatment-related adverse events was seen with a 3-day dosing protocol, with diarrhea/loose stools (5.9%) and vomiting (2.1%) as the most commonly reported adverse events. These side effects may be prevented or alleviated by taking azithromycin with food or milk.

Although serious allergic reactions (e.g., angioedema, anaphylaxis, Stevens Johnson Syndrome, toxic epidermal necrolysis) are rare, fatalities have been reported. If an allergic reaction occurs, the drug will be immediately discontinued and the appropriate therapy initiated. Patients will be advised to discontinue use immediately and contact their clinician if signs of an allergic reaction occur. This caution will be listed specifically in the informed consent document. Also indicated is the warning that, as with other anti-infective agents, use of azithromycin may result in overgrowth of non-susceptible bacteria or fungi, particularly *Clostridium difficile* in the colon. *Clostridium difficile* associated diarrhea (CDAD) may range in severity from mild diarrhea to fatal colitis. We will advise patients and parents about the possibility of bloody or moderate to severe watery diarrhea. Should this occur, the study medication will be stopped and the clinical center contacted. If CDAD is suspected or confirmed, azithromycin will be discontinued and appropriate fluid and electrolyte management, protein supplementation, and other medical therapy will be initiated as clinically indicated.

Because azithromycin is principally eliminated via the liver, parents or participating children will be carefully questioned about history of liver abnormalities. Because daily administration of azithromycin over 7 months has not been associated with increased liver enzymes and the dosing regimen used in this trial uses azithromycin for 5 days for each RTI (maximum dose of 3 courses), liver enzymes will not be measured routinely in this study.

Although prolonged cardiac repolarization and QT interval prolongation (imparting a risk of developing cardiac arrhythmia and torsades de pontes) are rarely observed with macrolide treatment, we will also carefully question parents about a history of cardiac abnormalities and arrhythmias. However, prolonged cardiac repolarization and QT interval have not been listed a specific concern for azithromycin given the lack of interaction with the P450 liver metabolism enzymes, although similar effects with azithromycin cannot be completely ruled out.

While interactions have not been reported between azithromycin and several drugs, specific studies evaluating the potential of drug-drug interactions are lacking. Because azithromycin may potentially alter other therapeutic drug levels, we will not enroll patients who are taking digoxin, ertotamine or dihydroergotamine, triazolam, carbamazepine, cyclosporine, hexobarbital, or phenytoin.

C. ADVERSE EVENTS UNRELATED TO RESPIRATORY SYMPTOMS/ASTHMA

Adverse events due to concurrent illnesses other than asthma may be grounds for withdrawal if the illness is considered significant by the study investigator or if the patient is no longer able to effectively participate in the study. Subjects experiencing minor intercurrent illnesses may continue in the study if the nature, severity, and duration of the illness are recorded and that any unscheduled medications required to treat the illness are recorded. Examples of minor illnesses include skin disorders such as atopic dermatitis and gastroenteritis. Medications are allowed for treatment of these conditions in accordance with the judgment of the responsible study physician. Patients will be asked to report to the clinical center the use of any prescription medication other than study medications so that appropriate adjustments can be made in coordination with the prescribing doctor.

Documentation of an adverse event unrelated to asthma will be recorded on an Adverse Event Report Form and will include the following information:

1. Description of the illness
2. Dates of the illness
3. Treatment of the illness and dates
4. Whether emergency treatment or hospitalization was required
5. Treatment outcome

D. ADVERSE EVENTS RELATED TO RESPIRATORY/ASTHMA EXACERBATIONS

The inclusion criteria require that all participants have experienced enough significant episodes previously to expect a similar pattern of illness the following year. All children in the trial will receive inhaled bronchodilators during the course of RTI and for rescue. All children will have action plans available, AsthmaNet physicians availability 24 hours a day for guidance as outlined in **Section V.H-J**.

VII. STATISTICAL DESIGN AND ANALYSIS

A. APRIL: OVERVIEW

The goal of APRIL is to test whether treatment with azithromycin, at the earliest sign of RTI, can reduce the risk of symptom progression. The primary outcome is the occurrence of treatment failure with respect to lower respiratory tract symptom progression. Although this outcome is binary for each RTI, the unit of analysis is the individual participant who may experience up to 4 RTIs during the course of the study. APRIL participation is terminated when APRIL treatment failure occurs or, if no treatment failure occurs, after the fourth RTI or at the end of follow-up, whichever occurs first. Therefore, the efficacy of the treatment can be quantified by counting the number of RTIs that do not result in treatment failure (i.e., have a successful outcome) and modeled using the discrete-time survival analysis framework, with RTI serving as the unit of time. This model assumes that every participant would eventually experience a treatment failure if followed through a sufficient number of RTIs so that the true number of successful RTIs is censored if a participant does not experience a treatment failure during the course of the study.

B. APRIL: ANALYSIS

The run-in period is considered the baseline evaluation period. Descriptive statistics (means and standard deviations, or medians and inter-quartile ranges) will be calculated for continuous baseline measures and frequency tables will be used to summarize categorical baseline measures.

PRIMARY ANALYSIS

The primary analysis will be conducted using the discrete-time survival analysis modeling framework using the RTI at which treatment failure occurred as the outcome variable and treatment assignment as the predictor variable of primary interest. Participants who do not have any RTIs will be treated as censored at time 0, while participants who have 4 RTIs without experiencing treatment failure will be treated as censored at time 4. Participants may be censored at other times due to dropout or end of follow-up. Drop-status will be assigned if the participant: voluntarily withdraws consent, is withdrawn from the study by physician discretion, experiences the criteria for treatment failure apart from an RTI, or experiences the criteria for treatment failure during an RTI, but prior to taking 2 doses of study medication (insufficient dosing). All of the censoring mechanisms will be considered non-informative with respect to treatment assignment. Clinical center and age group will be included as covariates that are independent of treatment assignment by design. Asthma predictive index status (API) will also be included as a covariate along with season during which the RTI occurred and day care or school attendance as time-dependent covariates.

Note: The APRIL protocol was originally designed as a 52-week study allowing participants to experience up to 3 RTIs instead of 4. The protocol was extended to 78 weeks in June 2012 because the North American 2011/2012 viral season was unusually mild and it was apparent that the power of both the APRIL and OCELOT studies had been compromised due to the unexpectedly low rate of RTIs in the study population. At that time, approximately one-half of the study population had been enrolled. Of those, 60% were still in the original 52-week APRIL follow-up and 40% had completed the 52-week APRIL follow-up. All participants enrolled after the protocol change entered the 78-week follow-up period. Participants enrolled before the protocol change and still in the 52-week follow-up at the time of the protocol change were invited to join the 78-week follow-up and reconsented if they agreed. Participants who declined to join the 78-week follow-up were permitted to complete the 52-week follow-up under their original consent.

Participants who had completed the 52-week follow-up or experienced a 3rd RTI prior to the protocol change were not invited to join the 78-week follow-up. These participants will be included in the primary analysis as if they had enrolled in the 78-week study, but dropped out after 52-weeks or following a 3rd RTI. These participants can be viewed as having a different censoring mechanism than those who entered the 78-week follow-up. This difference is due solely to study design considerations and is independent of treatment assignment, but may not be independent of the underlying rate of RTIs. Therefore, the primary analysis will incorporate an additional covariate in the form of an indicator variable signifying whether the participant was terminated from the study prior to the protocol change.

SECONDARY ANALYSES

Secondary analyses for the primary outcome will examine other characteristics, including demographics, genotype, viral infection and medical history, as covariates and as interactions with treatment assignment. Additional secondary analyses will examine possible treatment effects on other outcomes as described above in section II.B. Some of these are binary outcomes associated with RTI and will be analyzed using the discrete-time survival model. These include the occurrence of urgent care visits, ED visits, hospitalizations, side effects. Some outcomes are quantitative and will be analyzed using mixed-effects generalized linear models to account for the possibility of multiple measurements. These include measures of asthma-related symptoms such as albuterol use and frequency of missed school/daycare/parental work. Other outcomes are not associated with individual RTIs, such as quality of life and measures of asthma-related impairment, and will be summarized over the duration of the trial from the time of first RTI. Participants who do not experience an RTI are non-informative.

Other secondary analyses will include a pharmacoeconomic assessment reflecting the societal perspective for treatment of preschool children with recurrent wheezing episodes using azithromycin. There are several limitations for these analyses, particularly the potential lack of generalizability due to population selection and the fact that the protocol mandates closer monitoring of patients than would be expected in general practice. However, major advantages of economic analysis in randomized controlled clinical trials are that detailed assessments of prospectively defined resource utilization can be obtained and that treatment selection bias is eliminated by randomization. The goal of the cost-effectiveness analysis will be to estimate the incremental cost-effectiveness ratio for azithromycin. Cost-effectiveness acceptability curves will be produced in order to determine the probability that azithromycin is cost-effective under a range of willingness-to-pay scenarios.

C. APRIL: SAMPLE SIZE JUSTIFICATION

The target sample size for this protocol is 600 randomized children. The table below gives power for a two-sided test with 5% type-I error rate under various scenarios. Closed form power equations for the discrete-time survival analysis model with dropouts are not available. The estimates given in the table were calculated via Monte Carlo simulation with 500 replications. The following parameters were used for the simulations:

1. The number of RTIs per year under Poisson distribution – 2.75 was used for all simulations
2. The expected percent of participants lost during the 18 months of follow-up under exponential distribution – 20% was used for all simulations
3. The probability of meeting treatment failure criteria prior to second dose of study medication – 0.1, 0.2 or 0.3
4. The risk of treatment failure, per-RTI, in the placebo group, conditional on receiving at least 2 doses of study medication – 0.2, 0.25, 0.3 or 0.4
5. Relative risk of treatment failure for the azithromycin group compared to the placebo group (i.e., the effect size) – 0.65, 0.70 or 0.75

The expected number of RTIs and treatment failures utilized for the sample size calculations were selected based on the results of the previous CARE Network PEAK and AIMS studies and on recent trends in respiratory illnesses.

Probability of not receiving 2 doses	Placebo Group: Treatment Failure Risk per RTI	Placebo Group: Expected Percent of Participants having Treatment Failure	Power if per RTI relative risk with azithromycin is:		
			0.75	0.70	0.65
0.3	0.40	62%	87%	97%	99%
0.2	0.40	69%	95%	99%	99%
0.1	0.40	74%	96%	99%	99%
0.3	0.30	51%	75%	91%	97%
0.2	0.30	57%	85%	95%	98%
0.1	0.30	62%	89%	97%	99%
0.3	0.25	45%	65%	82%	95%
0.2	0.25	50%	75%	90%	96%
0.1	0.25	55%	83%	94%	98%
0.3	0.20	37%	56%	71%	86%
0.2	0.20	42%	68%	84%	94%
0.1	0.20	47%	72%	87%	95%

These results indicate that even under very conservative assumptions this study design is adequately powered if the true relative risk with azithromycin is not greater than 0.70. Under less conservative assumptions, this study is adequately powered if the relative risk with azithromycin is as high as 0.75. In addition to the participants who had a treatment failure and were included in the primary analysis, this number also includes those who met the treatment failure criteria before receiving 2 doses of study medication. It is important to note that RTIs are not equivalent to calendar time. Some participants may have had two RTIs and experienced treatment failure in the first 3 months of the study, while small number of participants who “dropped-out” prior to their first RTI actually completed the full 18 months of follow-up.

D. APRIL: INTERIM ANALYSES AND DATA MONITORING

The 600 children participating in APRIL will be enrolled over an 18-month period and each participant will be followed for up to one year. APRIL will be monitored by the AsthmaNet Data and Safety Monitoring Board (DSMB). The DSMB will receive any reports of serious adverse events as they occur throughout the course of the trial and will meet semi-annually to review non-serious adverse event data and quality control reports. No formal interim analyses for futility/efficacy are

planned. A feasibility analysis will be performed after 50% of the participants have completed at least 6 months of follow-up. Under uniform enrollment, this would be expected to occur after about 15 months of recruitment. The purpose of this analysis will be to check whether the assumptions regarding loss to follow-up, rate of RTI, and rate of treatment failure were appropriate. The two treatment arms will be combined for this analysis. Based on these results, the DSMB may elect to extend the sample size beyond 600.

VIII. SIGNIFICANCE

The purpose of this study is to provide definitive evidence regarding the potential use of azithromycin at the earliest signs of respiratory tract illness to prevent progression to clinically significant LRT episodes. Either negative or positive results would provide important new information to guide therapy. If APRIL fails to show any positive effect of azithromycin, there will be no justification for the continued and widespread prescription of this antibiotic in wheezy preschoolers, thus curtailing its frequent use, with favorable effects on anti-microbial resistance. If azithromycin is shown to be efficacious, we would have identified the first therapeutic approach with clearly demonstrated capacity to prevent severe LRT episodes in preschool children when used appropriately. To accomplish this latter goal, it is essential to design the trial in a way that, based on current knowledge regarding potential therapeutic mechanisms of azithromycin in acute LRTI, will increase the likelihood for this medicine to be effective. Initiation of therapy at the earliest signs of an episode is thus likely to be critical if azithromycin reduces episode severity through putative antiviral properties. Azithromycin's long biologic half-life results in 10 days of pharmacodynamic activity with 5 days of treatment. This property will allow for determination of the efficacy of azithromycin administration during the entire time of the episode, as pharmacologic activity will be present from the time of first administration (at the time of earliest symptom onset) to 10 days later. Thus, not only potential effects of azithromycin on the initial viral replication phase but also those on the subsequent neutrophilic inflammation will be tested in this trial.

IX. APPENDICES

APPENDIX 1: MODIFIED PARENTAL RESPIRATORY ILLNESS QUESTIONNAIRE

Please answer the following questions on your child's most recent episode of significant wheezing:

1. What was the very first symptom you noticed that led you to believe that your child was starting a respiratory illness? Please choose one of the categories from the general list provided. Then choose the symptom from the specific list within that category. If the very first symptom is not on the list, please indicate the very first symptom in the 'Other' space.

2.. What was the most important symptom you notice that made you feel certain the respiratory illness would lead to significant wheezing problems? Please circle one of the bolded symptoms on the list. If the symptom is not on the list, please indicate the symptom in the "Other" space of the bolded category that most appropriately categorizes the symptoms.

3. What were the two most important symptoms present when you began to start medications intended to lessen the symptoms? Please choose two of the unbolded symptoms on the list. If the symptom is not on the list, please indicate the symptom in the 'Other' space of the bolded category which most appropriately categorizes the symptoms. Do not circle two symptoms within the same bolded category.

Symptom List

General

A Fever:

Specific

- 1 any fever
- 2 high fever
- 3 skin feels warm/hot to touch
- 4 other _____

B Appearance changes:

- 1 dark circles under eyes
- 2 glassy eyes
- 3 watery eyes
- 4 other _____

C Behavior problems:

- 1 bedwetting
- 2 fussy/cranky/irritable
- 3 hyperactive
- 4 less active (won't play)
- 5 emotional/crying at everything/quick to emotional outburst
- 6 Short tempered/mean/angry
- 7 Nervousness/anxiety
- 8 other _____

- D Changes in sleep patterns:**
- 1 awakening during sleep
 - 2 sleepy during the day/lethargic
 - 3 sleep upright
 - 4 sleep walking
 - 5 other _____
- E Appetite changes:**
- 1 eating less/won't eat
 - 2 spitting-up/vomiting
 - 3 other _____
- F Nose symptoms:**
- 1 congested/stuffy
 - 2 runny
 - 3 sneezing
 - 4 other _____
- G Noisy breathing:**
- 1 hoarse voice
 - 2 snoring
 - 3 other _____
- H Cough A:**
- 1 infrequent
 - 2 mild
 - 3 not concerning
 - 4 other _____
- I Cough B:**
- 1 concerning
 - 2 constant
 - 3 interrupts activities
 - 4 interrupts sleep
 - 5 repetitive
 - 6 "THE asthma cough"
 - 7 other _____
- J Noisy chest:**
- 1 gurgling
 - 2 rattling
 - 3 wheezing
 - 4 other _____
- K Breathing problems:**
- 1 breathing worse
 - 2 not breathing well/trouble breathing
 - 3 other _____
- L Activity:**
- 1 decreased activity/tired/sleepiness/lethargy
 - 2 lack of interest in regular activities
 - 3 other _____

APPENDIX 2: WHEN TO BEGIN APRIL MEDICATIONS

- At the first 2 study visits, you were asked questions in order to find out what symptoms your child has at the start of a breathing illness such as a cold that you think usually leads to a wheezing illness.
- These symptoms will be used to develop a plan just for YOUR CHILD to start the APRIL medicine.
- When your child develops these symptoms (listed on the APRIL ACTION PLAN), you will begin to give your child the APRIL respiratory illness medicine and do the following:
 - Obtain the nasal sample from your child on Day 1 and Day 4 of each RTI in which the respiratory illness medicine is started.
 - Once you start the respiratory illness medicine, please continue it for the full 5 days, even if your child gets much better.
 - If you forget to give a dose of APRIL medicine, give the usual dose the next day (do not double the dose) and continue until a total of 5 doses have been given.
- If you feel that the kind of symptoms your child has with breathing illnesses change during the study, please inform your child's coordinator in order to modify the PLAN for use with future RTI.


APPENDIX 3: WHEN TO BEGIN OPEN-LABEL CORTICOSTEROID MEDICATIONS

- Based on the APRIL Action plan, if YOUR CHILD develops the following symptoms:
 - severe respiratory problems,
 - albuterol treatments given more frequently than every 4 hrs after the first hour or albuterol therapy is not helping you child's symptoms,
 - continuing to have significant cough or wheeze for 5 days or more since you started APRIL therapy,
- You will call the AsthmaNet Clinical center or after-hours nurse triage center to discuss whether OPEN-LABEL CORTICOSTEROID medicine should be started and do the following:
 - Once you start the OPEN-LABEL CORTICOSTEROID medicine, please continue it for the full 4 days, even if your child gets much better.
 - If you forget to give a dose of respiratory illness medicine, use the following guide to taking the next dose:
 - If an entire day is missed, continue to give the usual dose the next day until you are finished with all 4 days of the respiratory illness medicine.
- If you feel that the kind of symptoms your child has with breathing illnesses change during the study, please inform your child's coordinator in order to modify the PLAN for use with future RTI.


APPENDIX 4. APRIL TREATMENT FAILURE AND STARTING ORAL CORTICOSTEROID TREATMENT FLOWCHART


FLOW CHART PAGE 1

SICK FLOW CHARTS




FLOW CHART PAGE 2





FLOW CHART PAGE 4



Notes:
 **Albuterol treatment= one 2.5 mg neb or 2 puffs MDI
 ***3 back-to-back=3 albuterol treatments every 15-20 min within 1 hour

APPENDIX 5. OCELOT FUTILITY ANALYSIS



Date: March 20, 2013
From: APRIL-OCELOT Protocol Working Group on behalf of the Steering Committee
To: AsthmaNet Data and Safety Monitoring Board
Re: Interim Analysis and Proposed Modifications to the APRIL-OCELOT Trial

The APRIL-OCELOT trial began enrolling participants on April 4, 2011, and as of March 7, 2013, 540 of the total 600 expected participants have been randomized. Of these, 238 are still in APRIL follow-up, 188 completed the study, and 114 were termed early due to asthma exacerbation, developing persistent symptoms or lost to follow-up. There currently are 334 total years of follow-up.

APRIL Interim Analysis

With respect to the APRIL portion of the study, as specified on page 52 of the protocol: *No formal interim analyses for futility/efficacy are planned. A feasibility analysis will be performed after 50% of the participants have completed at least 6 months of follow-up. Under uniform enrollment, this would be expected to occur after about 15 months of recruitment. The purpose of this analysis will be to check whether the assumptions regarding loss to follow-up, rate of RTI, and rate of treatment failure were appropriate. The two treatment arms will be combined for this analysis. Based on these results, the DSMB may elect to extend the sample size beyond 600.*

To date, 282 participants (52%) have completed at least 6 months of follow-up and following is a summary of the planned interim analysis:

1. The protocol assumption was that up to 15% of participants would have dropped out early at this point in the study, while in fact 23% have dropped out early. If that trend continues, we expect 28% will have dropped out early at the end of the study.
2. To date, 384 participants have experiences at total of 719 respiratory tract infections (RTIs) and used a total of 719 courses of blinded APRIL study treatment.
3. To date, 70 of the 719 APRIL treatment courses have resulted in treatment failure, which is the primary outcome for APRIL.

The sample size calculations (pages 49-50 of APRIL-OCELOT the protocol) showed the expected power over a range of potential scenarios for the expected risk of APRIL treatment failure. The table below shows the expected number of APRIL treatments used and APRIL treatment failures at this point in the study. That is, with 540 randomized participants followed for the 334 total years. The rows shaded in green denote scenarios where the APRIL failure rate is the same for both the placebo and active arms, while the rows shaded in blue denote scenarios where the relative risk for the active arm compared to the placebo arm is 0.65, which was the most optimistic treatment effect in the protocol power analysis. As can be seen, when the treatment failure risk is higher, the total

number of expected APRIL treatments is lower because once the treatment failure outcome is achieved, study participation is completed and no additional APRIL treatments can be used. None of the scenarios examined in the table fit well with the observed data. The observed number of APRIL treatments fits well with the scenarios having higher treatment failure risk, but the observed number of APRIL treatment failures fits well with the scenarios having lower treatment failure risk.

Hypothetical rate of RTI (per child-year)	Hypothetical APRIL Treatment Failure Risk		Total number of APRIL treatments used in both groups combined		Total number of APRIL treatment failures in both groups combined	
	Placebo	Azithromycin	Expected	Observed	Expected	Observed
2.75	0.40	0.40	705	719	253	70
		0.26	749		221	
	0.20	0.20	836		149	
		0.13	861		127	
	0.15	0.15	872		117	
		0.098	892		99	
	0.10	0.10	910		81	
		0.065	924		68	

One explanation for the lower than expected number of APRIL treatments used to date would be is a lower than expected rate of RTI. Indeed, in May 2012, the DSMB approved a protocol change extending the total length of follow-up from 12 to 18 months and increasing the maximum number of APRIL courses from 3 to 4 due to concerns that the RTI rates would be too low following a mild 2011/2012 viral season. At the time, the Steering Committee anticipated that future viral seasons would yield higher rates of RTIs and that the overall rate of RTIs would be 2.75 per child-year by the time the study is completed. However, the full effects of those protocol changes likely have not been seen yet. The table below shows the same treatment failure risk scenarios as in the table above, but with a lower rate of RTI

Hypothetical rate of RTI (per child-year)	Hypothetical APRIL Treatment Failure Risk		Total number of APRIL treatments used in both groups combined		Total number of APRIL treatment failures in both groups combined	
	Placebo	Azithromycin	Expected	Observed	Expected	Observed
2.00	0.40	0.40	591	719	212	70
		0.26	622		184	
	0.20	0.20	682		122	
		0.13	699		103	
	0.15	0.15	707		94	
		0.098	721		79	
	0.10	0.10	734		65	
		0.065	743		54	

Several of these scenarios are consistent with the observed number of APRIL treatments used and number of APRIL treatment failures. In particular, the scenario under which the placebo and active

treatment failure rate are both 0.1 and the scenario under which the placebo treatment failure rate is 0.15 and active treatment failure rate is lower. Of course, there are other scenarios that would also be consistent with the observed data. The point of this table is to demonstrate that the only scenarios that are consistent with the observed data are those where both the placebo and active treatment failure rates are less than 0.20. This is important because 0.20 was the lowest treatment failure rate considered in the protocol sample size calculations.

The AsthmaNet Steering Committee feels there is evidence that the sample size calculations were likely based on assumptions that have not been borne out during the trial. In particular, that both the assumed rate of RTI and the assumed risk of APRIL treatment failure were overly optimistic. New power calculations based on parameters consistent with the observed data (drop-out rate of 28% and RTI rate of 2.0) indicate that under the most optimistic effect size for Azithromycin originally put forward, a 35% risk reduction, the current sample size of 600 has 71% power if the placebo treatment failure rate is 0.10, 79% power if the placebo treatment failure rate is 0.13 and 86% power if the placebo treatment failure rate is 0.15. All of these are consistent with the observed number of APRIL treatment failures to date. The AsthmaNet Steering Committee recommends not increasing the APRIL sample size because the study is reasonably powered, at approximately 80%, under conditions that we now have evidence about, and for what was originally felt to be a credible Azithromycin effect size.

OCELOT Interim Analysis

With respect to the OCELOT portion of the study, as specified on page 56 of the protocol: *No formal interim analyses for futility/efficacy are planned. A feasibility analysis for APRIL is planned after 50% of the participants have completed at least 6 months of APRIL follow-up. A feasibility analysis for OCELOT will be done simultaneously. The purpose of the APRIL feasibility analysis will be to check whether the assumptions regarding loss to follow-up, rate of RTI, and rate of treatment failure were appropriate. The two treatment arms will be combined for this analysis. The rate of treatment failure in APRIL is directly relevant to the feasibility of OCELOT. Although it will not be possible to estimate the treatment failure rate in the APRIL placebo arm, the combined estimate should allow a conservative assessment because the APRIL treatment failure rate in the placebo arm is not expected to be significantly smaller than that of the azithromycin arm. Based on these results, the DSMB may elect to extend the APRIL sample size beyond 600, or to declare OCELOT infeasible and stop the study.*

As detailed above, to date, 70 APRIL treatment failures have occurred. Of these, 39 resulted in OCELOT starts and 31 resulted in acute study failure (i.e., use of open-label prednisolone). There were an additional 9 OCELOT starts that occurred on the same day as an APRIL start. These do not count as APRIL treatment failures because the patient did not receive the minimum 2 doses of APRIL medication, but could be included in the primary analysis for OCELOT. Therefore, there have been 48 OCELOT starts that could be used in the primary analysis (recall that only those OCELOT starts that came from patients on APRIL placebo will actually be used in the primary analysis). At this point in the study, we expected to have seen at least 137 OCELOT starts and we assumed for the OCELOT power calculations that at least one-half of them, about 70, would have come from the APRIL placebo arm. We do not know how many of those 48 came from patients on APRIL placebo. Even in the best-case scenario where the vast majority of the 48 came from the APRIL placebo arm, the actual number of OCELOT starts is below the expected number on which the OCELOT power calculations were based.

At least as concerning is the fact that 31 of the APRIL treatment failures resulted in acute study failures rather than OCELOT starts. The majority of these acute study failures occurred when the parent took the child to urgent care or ER where a physician prescribed open-label prednisone. Although we cannot be sure, it seems likely that the children who experienced acute study failure were generally sicker than the children who initiated OCELOT. If that is the case, then the actual OCELOT study participants will not be representative of the intended study population and the external validity of the study will be compromised.

After careful consideration, the AsthmaNet Steering Committee proposes that the OCELOT study be declared infeasible and halted. The primary reasons are: 1) likelihood that the study will be underpowered due to inadequate sample size and less symptomatic patients having insufficient potential to show a treatment effect, and 2) concern that external validity will be compromised due to the high proportion of patients being treated off-protocol with open-label prednisolone. If the study is halted early, the APRIL-OCELOT Protocol Working Group intends to publish the study design and report the reasons we think this study was unsuccessful to inform our research colleagues.

X. REFERENCES

1. Akinbami L. The state of childhood asthma, United States, 1980-2005. *Adv Data* 2006;1-24.
2. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006;354:1985-97.
3. National Asthma Education and Prevention Program. Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: US Department of Health and Human Services; 2007.
4. Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. *J Allergy Clin Immunol* 2008;122:1127-35.
5. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. *Arch Dis Child* 1993;68:85-7.
6. Svedmyr J, Nyberg E, Thunqvist P, Asbrink-Nilsson E, Hedlin G. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. *Acta Paediatr* 1999;88:42-7.
7. Wilson N, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. *Arch Dis Child* 1990;65:407-10.
8. Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. *N Engl J Med* 2009;360:339-53.
9. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. *Am J Respir Crit Care Med* 2005;171:315-22.
10. Robertson CF, Price D, Henry R, et al. Short Course Montelukast for Intermittent Asthma in Children: a Randomised Controlled Trial. *Am J Respir Crit Care Med* 2007;175:323-9.
11. Kozyrskyj AL, Dahl ME, Ungar WJ, Becker AB, Law BJ. Antibiotic treatment of wheezing in children with asthma: what is the practice? *Pediatrics* 2006;117:e1104-10.
12. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. *N Engl J Med* 2006;354:1589-600.
13. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. *Lancet* 2002;360:978-84.
14. Gaylor AS, Reilly JC. Therapy with macrolides in patients with cystic fibrosis. *Pharmacotherapy* 2002;22:227-39.
15. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003;290:1749-56.
16. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2010;303:1707-15.
17. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. *Respiration* 1991;58:145-9.
18. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. *Respiration* 1996;63:42-8.
19. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. *Thorax* 1997;52:915-8.
20. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. *Chest* 1994;106:1116-23.
21. Message SD, Johnston SL. Viruses in asthma. *Br Med Bull* 2002;61:29-43.

22. Gern JE, Martin MS, Anklam KA, et al. Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. *Pediatr Allergy Immunol* 2002;13:386-93.
23. Kobayashi Y. The role of chemokines in neutrophil biology. *Front Biosci* 2008;13:2400-7.
24. Lacy P, Eitzen G. Control of granule exocytosis in neutrophils. *Front Biosci* 2008;13:5559-70.
25. Bentley JK, Newcomb DC, Goldsmith AM, Jia Y, Sajjan US, Hershenson MB. Rhinovirus activates interleukin-8 expression via a Src/p110beta phosphatidylinositol 3-kinase/Akt pathway in human airway epithelial cells. *J Virol* 2007;81:1186-94.
26. Norzila MZ, Fakes K, Henry RL, Simpson J, Gibson PG. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. *Am J Respir Crit Care Med* 2000;161:769-74.
27. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma. *Am J Respir Crit Care Med* 2008;177:148-55.
28. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. *Eur Respir J* 2010;Online ahead of print.
29. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* 2005;201:937-47.
30. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat Med* 2006;12:1023-6.
31. Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. *J Allergy Clin Immunol* 2004;114:239-47.
32. Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. *Pediatr Infect Dis J* 2005;24:S217-22, discussion S20-1.
33. Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. *Pediatrics* 2003;112:382-97.
34. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database Syst Rev* 2007;CD000195.
35. Grant C, Duggan A, DeAngelis C. Independent parental administration of prednisone in acute asthma: A double-blind, placebo-controlled, crossover study. *Pediatrics* 1995;96:224-9.
36. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. *Lancet* 2003;362:1433-8.
37. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. *N Engl J Med* 2009;360:329-38.
38. Bush A. Practice imperfect--treatment for wheezing in preschoolers. *N Engl J Med* 2009;360:409-10.
39. Grigg J. Role of systemic steroids in acute preschool wheeze. *Arch Dis Child*:Published Online First on April 6, 2010.
40. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. *Paediatr Respir Rev* 2005;6:227-35.
41. Ekici A, Ekici M, Erdemoglu AK. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. *J Asthma* 2002;39:181-5.
42. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. *Pulm Pharmacol Ther* 2009;22:467-72.
43. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. *Chest* 1991;99:670-3.

44. Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. *Chest* 1994;106:458-61.
45. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. *J Asthma* 1995;32:191-7.
46. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. *J Asthma* 1997;34:211-7.
47. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. *Ann Allergy Asthma Immunol* 2000;84:594-8.
48. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with *Chlamydia pneumoniae*. *Am J Respir Crit Care Med* 2001;164:536-41.
49. Kraft M, Cassell GH, Pak J, Martin RJ. *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in asthma: effect of clarithromycin. *Chest* 2002;121:1782-8.
50. Kostadima E, Tsiodras S, Alexopoulos EI, et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. *Eur Respir J* 2004;23:714-7.
51. Piacentini GL, Peroni DG, Bodini A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. *Allergy Asthma Proc* 2007;28:194-8.
52. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2008;177:148-55.
53. Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. *J Allergy Clin Immunol* 2008;122:1138-44 e4.
54. Fonseca-Aten M, Okada PJ, Bowlware KL, et al. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial. *Ann Allergy Asthma Immunol* 2006;97:457-63.
55. Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. *Eur Respir J* 2007;29:91-7.
56. Beigelman A, Gunsten S, Mikols CL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. *Chest* 2009;136:498-506.
57. Sato K, Suga M, Akaike T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. *Am J Respir Crit Care Med* 1998;157:853-7.
58. Beigelman A MC, Gunsten S, Cannon CL, Walter MJ. . Azithromycin Attenuates Airway Inflammation in a Mouse Model of Viral Bronchiolitis. . 2010, under review.
59. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. *Eur Respir J*.
60. Asada M, Yoshida M, Suzuki T, et al. Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. *Antiviral Res* 2009;83:191-200.
61. Miyamoto D, Hasegawa S, Sriwilaijaroen N, et al. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. *Biol Pharm Bull* 2008;31:217-22.
62. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in *Pseudomonas* endobronchial infection. *Am J Respir Crit Care Med* 2004;170:1331-9.
63. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. *Am J Respir Crit Care Med* 1997;156:266-71.
64. Kawasaki S, Takizawa H, Ohtoshi T, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. *Antimicrob Agents Chemother* 1998;42:1499-502.

65. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. *Am J Respir Crit Care Med* 2003;168:581-7.
66. Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. *Chest* 2008;134:20-9.
67. Hatipoglu U, Rubinstein I. Low-dose, long-term macrolide therapy in asthma: An overview. *Clin Mol Allergy* 2004;2:4.
68. Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. *Pediatrics* 1993;92:513-8.
69. Brunette M, Lands L, Thibodeau L-P. Childhood asthma: Prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. *Pediatrics* 1988;81:624-9.
70. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: A meta-analysis. *Pediatrics* 2000;105:E44.
71. Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. *N Engl J Med* 2007;357:331-9.
72. Jartti T, Lehtinen P, Vanto T, et al. Efficacy of prednisolone in children hospitalized for recurrent wheezing. *Pediatr Allergy Immunol* 2007;18:326-34.
73. Fost DA, Leung DY, Martin RJ, Brown EE, Szeffler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. *J Allergy Clin Immunol* 1999;103:1031-5.
74. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. *Ann Pharmacother* 1998;32:785-93.
75. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. *Pediatr Infect Dis J* 2004;23:S135-9.
76. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. *Antimicrob Agents Chemother* 1995;39:1875-7.
77. Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. *Antimicrob Agents Chemother* 1993;37:314-6.
78. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. *Int J Antimicrob Agents* 2001;18 Suppl 1:S11-5.
79. Danesi R, Lupetti A, Barbara C, et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. *J Antimicrob Chemother* 2003;51:939-45.
80. Kayani S, Shannon DC. Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids. *Chest* 2002;122:624-8.
81. Dawson KL, Carter ER. A steroid-induced acute psychosis in a child with asthma. *Pediatr Pulmonol* 1998;26:362-4.
82. Dolan L, Kesarwala H, Holroyde J, Fischer T. Short-term, high-dose, systemic steroids in children with asthma: The effect on the hypothalamic-pituitary-adrenal axis. *J Allergy Clin Immunol* 1987;80:81-7.
83. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. *J Bone Miner Res* 2003;18:913-8.
84. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. *N Engl J Med* 2000;343:689-94.
85. Schuh S, Dick PT, Stephens D, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. *Pediatrics* 2006;118:644-50.
86. Nelson KA, Smith SR, Trinkaus K, Jaffe DM. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. *Pediatr Emerg Care* 2008;24:21-7.

87. Grigg J. Role of systemic steroids in acute preschool wheeze. *Arch Dis Child*.
88. Prevention CfDca. National Surveillance for Asthma - United States, 1980-2004. *MMWR, Surveillance Summaries* 2007;56.
89. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;162:1403-6.
90. Martinez F, Wright A, Taussig L, Holberg C, Halonen M, Morgan W. Asthma and wheezing in the first six years of life. *N Engl J Med* 1995;332:133-8.
91. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. *Clin Infect Dis* 2005;40:1748-55.
92. Blandizzi C, Malizia T, Batoni G, et al. Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. *Antimicrob Agents Chemother* 2002;46:1594-6.
93. Kelly HW. What is the dose of systemic corticosteroids for severe asthma exacerbations in children? *Pediatr Asthma Allergy Immunol* 2009;22:75-9.
94. Harris JB, Weinberger MM, Nassif E, Smith G, Milavetz G, Stillerman A. Early intervention with short courses of prednisone to prevent progression of asthma in ambulatory patients incompletely responsive to bronchodilators. *J Pediatr* 1987;110:627-33.
95. Deshpande A, McKenzie SA. Short course of steroids in home treatment of children with acute asthma. *Br Med J (Clin Res Ed)* 1986;293:169-71.
96. Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. *Arch Dis Child* 2010;95:146-9.
97. Yildirim ZK, Buyukavci M, Eren S, Orbak Z, Sahin A, Karakelleoglu C. Late side effects of high-dose steroid therapy on skeletal system in children with idiopathic thrombocytopenic purpura. *J Pediatr Hematol Oncol* 2008;30:749-53.
98. Srivastava RN, Vasudev AS, Bagga A, Sunderam KR. Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. *Pediatr Nephrol* 1992;6:247-50.
99. Shapiro GG, Furukawa CT, Pierson WE, Gardinier R, Bierman CW. Double-blind evaluation of methylprednisolone versus placebo for acute asthma episodes. *Pediatrics* 1983;71:510-14.
100. Ducharme FM, Chalut D, Plotnick L, et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. *J Pediatr* 2008;152:476-80, 80 e1.
101. Schuh S, Willan AR, Stephens D, Dick PT, Coates A. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. *J Pediatr* 2009;155:795-800.
102. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. *Thorax* 2000;55:1023-7.
103. Hacking D, Knight JC, Rockett K, et al. Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. *Genes Immun* 2004;5:274-82.
104. Goetghebuer T, Isles K, Moore C, Thomson A, Kwiatkowski D, Hull J. Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis. *Clin Exp Allergy* 2004;34:801-3.
105. Papadopoulos NG, Xepapadaki P, Mallia P, et al. Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. *Allergy* 2007;62:457-70.
106. Lemanske RF, Jr., Jackson DJ, Gangnon RE, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol* 2005;116:571-7.
107. Jartti T, Lehtinen P, Vuorinen T, et al. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. *Emerg Infect Dis* 2004;10:1095-101.

108. Kotaniemi-Syrjanen A, Vainionpaa R, Reijonen TM, Waris M, Korhonen K, Korppi M. Rhinovirus-induced wheezing in infancy--the first sign of childhood asthma? *J Allergy Clin Immunol* 2003;111:66-71.
109. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med* 2008;178:667-72.
110. Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema. *J Allergy Clin Immunol* 2007;119:570-5.
111. Rivera-Spoljaric K, Chinchilli VM, Camera LJ, et al. Signs and symptoms that precede wheezing in children with a pattern of moderate-to-severe intermittent wheezing. *J Pediatr* 2009;154:877-81 e4.
112. Baquero F. Evolving resistance patterns of *Streptococcus pneumoniae*: a link with long-acting macrolide consumption? *J Chemother* 1999;11 Suppl 1:35-43.
113. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. *Infection* 2001;29:251-6.
114. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant *Streptococcus pneumoniae*. *Emerg Infect Dis* 2005;11:829-37.
115. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in *Streptococcus pneumoniae*. *J Clin Microbiol* 2002;40:159-64.
116. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. *J Antimicrob Chemother* 2002;49:61-8.
117. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H. Macrolide and azithromycin use are linked to increased macrolide resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2006;50:3646-50.
118. Oostenbrink R, Jansingh-Piepers EM, Raat H, et al. Health-related quality of life of pre-school children with wheezing illness. *Pediatr Pulmonol* 2006;41:993-1000.
119. Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. *J Clin Microbiol* 2002;40:4337-9.
120. White IR, Bamias C, Hardy P, Pocock S, Warner J. Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. *Stat Med* 2001;20:2995-3008.